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ABSTRACT 
The overarching goal of this work is to understand the contribution of the stroma 
to pancreatic tumorigenesis. Pancreatic cancer is among the deadliest of human 
malignancies and few specific treatments exist for this disease.  Median survival 
following diagnosis is six months, a dismal prognosis that has not changed in fifty years. 
A hallmark of pancreatic cancer is an extensive desmoplastic stroma consisting of 
fibroblasts, immune cells, and extracellular matrix. The signaling pathways and cellular 
components involved in inducing this desmoplastic reaction are an area of active 
investigation, with the hope of elucidating pathways to target in the clinic.  
Overexpression of the Hedgehog (HH) ligand occurs in roughly 75% of human 
pancreatic cancers.   Interestingly, HH ligands secreted by the tumor cells act on the 
tumor stroma to activate signaling in a paracrine manner.  However, pathway 
components that activate hedgehog signaling in the target cells are not fully elucidated, 
and represent potential druggable targets.  
In the first part of this dissertation, I determined the function of three HH co-
receptors, Boc, Cdon, and Gas1, on pancreatic tumor growth. While inhibition of HH 
signaling proved effective in early preclinical tests, clinical trials in humans were 
terminated due to acceleration of disease. My work indicated that the dosage of HH 
signaling is an important consideration in pancreatic cancer; while a complete blockade 
xvii 
 
of the pathway abrogated tumor growth, partial inhibition, such as that observed in the 
clinic, led to larger, more vascular tumors, which may account for the disappointing 
clinical trials.  Next, I studied the role of the HH pathway on pancreatitis and recovery. 
Pancreatitis is a risk factor for pancreatic cancer, and currently no treatment beyond 
palliative care exists for a disease characterized by progressive fibrosis and loss of 
tissue function. While descriptive reports have identified HH signaling in pancreatitis, 
studies as to its functional importance are lacking. Here, I identify a role for Gli1, a 
transcription factor activated by HH signaling, in pancreatitis and repair. Lastly, I 
characterized the role of the mesenchymal stem cell (MSC) in pancreatic cancer. 
Fibroblasts in the tumor microenvironment are treated as a homogenous group of cells, 
despite evidence that multiple subtypes exist. One such subtype is the MSC, a 
multipotent cell that has profound effects on tumorigenesis in several solid tumors. In 
pancreatic cancer, I identified a role for MSCs to direct the behavior of another stromal 
cell type, the macrophage, with the ultimate effect of promoting tumor growth.   
Taken together, this dissertation work will provide insight into the complex and 
dynamic microenvironment of pancreatic cancer.  
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CHAPTER ONE 
Introduction1 
Pancreatic Cancer 
Current Outlook 
Pancreatic cancer is a highly malignant disease with a median survival of 6 
months. Fewer than 5% of patients survive 5 years post-diagnosis, and only 15% of 
patients qualify for a surgical resection of the tumor, which is currently the most effective 
clinical option (1). Even among patients who qualify for resection and adjuvant 
chemotherapy, the median survival rate is only two years (2). Unfortunately, the 
currently used drug regimen is only marginally more efficacious than palliative care. 
While pancreatic cancer is currently the fourth leading cause of cancer deaths in the 
United States, it is expected to surpass breast, prostate and colorectal cancers to 
become the second leading cause of cancer deaths by 2030 (3,4).  Thus, a better 
understanding of pancreatic tumor biology is imperative for developing much-needed 
treatments. 
Overview 
                                                          
1Portions of this chapter have been submitted as an invited review to Cellular and 
Molecular Life Sciences: Mathew, E, Allen BA, and Pasca di Magliano, M. Tentative 
title: Hedgehog Signaling in Pancreatic Cancer 
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Pancreatic cancer, or pancreatic adenocarcinoma, arises from the exocrine 
pancreas and is the focus of this dissertation. The vast majority of pancreatic 
malignancies arise from the exocrine compartment. In contrast, cancers arising from the 
endocrine pancreas, known as pancreatic neuroendocrine tumors (PNETs), are rarer, 
but have a much better prognosis (5). Pancreatitis is a known risk factor for pancreatic 
cancer, and is the leading cause for gastrointestinal-related hospitalization in the United 
States (6,7). There are two forms of pancreatitis - acute and chronic. Both are 
characterized by improper production and activation of digestive enzymes in the 
pancreas, leading to acinar cell loss and fibroinflammatory infiltration. Unlike acute 
pancreas, which resolves over time, chronic pancreatitis requires continued medical 
intervention due to irreversible fibrosis and progressive loss of both endocrine and 
exocrine pancreas. However, only 5% of those suffering from chronic pancreatitis 
progress to pancreatic cancer (8). 
 Pancreatic cancer is thought to progress through precursor lesions that have 
been characterized both histologically and based on their gene mutation profile. The 
most common precursor lesion is the Pancreatic Intraepithelial Neoplasia (PanIN), 
although other neoplasms, such as Intraductal mucinous papillary neoplasm (IMPNs) 
and mucinous cystic neoplasms (MCNs) are also known to progress to cancer, although 
rarely  (for review, see (9) or (10)). PanINs are categorized into stages 1 through 3, 
based on increasing cellular atypia.  Almost all cases of pancreatic cancer are linked to 
an activating mutation in the GTPase KRAS, most commonly G12D and G12V (11-13), 
which are observed starting in low-grade PanIN lesions. Higher grades of PanIN lesions 
are also associated with loss of tumor suppressors including P53, INK4a/ARF and 
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SMAD4 (14-16). Along with PanIN progression, pancreatic cancer is characterized by a 
prominent desmoplasia – the accumulation of activated fibroblasts, extracellular matrix, 
and immune cells that persist throughout tumorigenesis. Up to 90% of a bulk tumor can 
consist of this reactive stroma, which is considered the highest of all solid epithelial 
malignancies (1). 
Treatment Options 
Pancreatic cancer is largely refractory to chemotherapy. The cancer cells 
themselves are resistant to apoptosis-inducing agents (17), and the reactive stroma 
creates a poorly perfused environment that nurtures tumor growth and suppresses the 
immune system (for review, see (18)). Along with a high degree of reactive stroma, 
pancreatic cancer is characterized by hypovascularity; tumors have significantly fewer 
functional blood vessels than normal pancreas (19).  Gemcitabine has long been the 
standard of care for pancreatic cancer (recently replaced by Folfirinox). However, most 
patients have little clinical response to this agent.  An emerging mode of treatment is the 
combination of agents that target both the tumor itself as well as signals from the 
microenvironment (for review, see (1)). While such approaches have shown efficacy in 
mouse models of pancreatic cancer, they remain unproven in the clinical setting.  
Mouse Models of Pancreatic Cancer 
Mouse models of pancreatic cancer have provided further insight into the cellular 
and molecular mechanisms that drive progression, maintenance, and metastasis of 
pancreatic cancer. The models that are considered most faithful to the human disease 
are based on the expression of an oncogenic form of Kras, usually a KrasG12D allele, 
4 
 
using a pancreas epithelium-specific promoter (for review, see (20)). The most 
commonly used model, called the KC mouse, combines a pancreas-specific Cre, such 
as Pft1a-Cre or Pdx1-Cre, with a conditional mutant KrasG12D allele inserted into its 
endogenous locus (21). Notwithstanding the expression of oncogenic Kras starting 
during embryonic stages, KC mice are born with a normal pancreas. However, over 
time, PanIN lesions do develop (21). Tumor formation in KC mice is rare. The deletion 
of P53 or presence of a mutant form of P53 (R172H) creates the KPC mouse and 
accelerates both PanIN and tumor formation (22).  The KPC mouse also replicates the 
resistance to gemcitabine commonly observed in human patients (19). Other pancreatic 
cancer models combine KC mice with deletion of other tumor suppressors such as 
CDKN2a or PTEN (23,24).  
Alternatively, PanIN progression can be accelerated in KC mice by inducing 
pancreatitis. Administration of the cholecystokinin (CCK) agonist caerulein induces the 
excessive secretion and premature activation of digestive enzymes that in turn causes 
acinar cell death, which leads to acinar de-differentiation to duct-like cells in a process 
known as acinar-ductal metaplasia (ADM) (25). Caerulein-induced pancreatitis is 
characterized by edema and infiltration of immune cells. Wildtype mice undergo tissue 
repair within a week of caerulein administration.  However, KC mice do not undergo 
repair; instead, the pancreatitis synergizes with oncogenic Kras to drive the 
development of low-grade PanIN lesions and the accumulation of desmoplastic stroma.   
The models described above all feature continuous activation of oncogenic Kras 
upon Cre expression, which occurs during pancreatic development (21,22). A different 
model of pancreatic cancer is the iKras* mouse. Expression of KrasG12D in this model is 
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inducible and reversible (26).  Like KC mice, iKras* mice develop PanINs sporadically 
and with long latency, but this process can be accelerated by inducing CCK-mediated 
pancreatitis. Interestingly, if oncogenic Kras is inactivated at early stages of PanIN-
development, the pancreas undergoes full recovery. The acinar cells re-differentiate, 
and the fibroinflammatory stroma completely resolves away (26). Thus, the iKras* 
mouse represents a system to study the pathogenesis of pancreatic cancer during 
initiation and progression, but also tissue dynamics following Kras inactivation. Both the 
iKras* and KPC mice replicate the salient features of human disease including aberrant 
secretion of HH ligand and accumulation of desmoplastic stroma (22,27).  
Hedgehog Signaling in the Pancreas 
Hedgehog Pathway Overview 
The Hedgehog (HH) pathway is highly conserved and plays an important role in 
a wide range of physiological processes. During development, HH signaling acts as a 
classic morphogen to define specific cell fates in a concentration- and time-dependent 
manner (for review, see (28)). The Hedgehog (Hh) gene was originally identified in a 
mutagenesis screen in Drosophila; larvae containing homozygous mutations in Hh 
display segmentation defects resulting in a continuous lawn of denticles (29). Unlike 
Drosophila, which possesses a single Hh gene, mammals have three: Sonic Hedgehog 
(Shh), Indian Hedgehog (Ihh), and Desert Hedgehog (Dhh). During mammalian 
development, expression of these three Hh genes depends on tissue and temporal 
context. Shh, the best-studied and most widely expressed of the three, is expressed in a 
broad range of tissues throughout embryonic development. Ihh expression is more 
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restricted than Shh, and has been best-studied in the context of endochondral bone 
formation (30). Dhh expression is largely restricted to the testes where it is essential for 
spermatogenesis (31), although it also controls peripheral nerve sheath formation (32).   
HH pathway activity depends on genes involved in the formation of primary cilia. 
All three ligands initiate canonical HH signaling by binding to the 12-pass 
transmembrane protein Patched 1 (PTCH1), located in the ciliary membrane. In the 
absence of HH ligand, PTCH1 inhibits the function of another 7-pass transmembrane 
protein Smoothened (SMO). Binding of HH ligand to PTCH1 triggers its endocytosis, 
thus abrogating SMO inhibition. SMO can then localize to the cilia (33), where it 
mediates HH signal transduction through activation of the GLI family of transcription 
factors. As another level of pathway regulation, the protein Supressor of Fused (SUFU) 
can sequester GLI proteins in the cytoplasm, thereby controlling their transcriptional 
activity (34,35,36) (for pathway schematic, see Figure 1.1). 
In mammals, there are three GLI proteins (GLI1, GLI2, and GLI3) with different 
functional properties. While GLI1 functions exclusively as a transcriptional activator, 
GLI2 and GLI3 can act as either transcriptional activators or repressors. Genetic studies 
indicate that GLI2 functions primarily as a transcriptional activator, while GLI3 acts 
mainly as a transcriptional repressor (37,38). Although GLI target genes are not fully 
elucidated, a number of HH pathway genes, including Gli1, Ptch1, Ptch2 and Hhip are 
direct transcriptional targets of the pathway (28), thus providing an additional 
mechanism of feedback regulation of the pathway activity.  
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More recently, screens in Shh mutant mice identified additional co-receptors that 
also bind HH ligands. These receptors, GPI-anchored Growth arrest-specific 1 (GAS1), 
along with single pass transmembrane CAMrelated/down-regulated by oncogenes 
(CDON), and Brother of Cdo (BOC), were all shown to all cooperate with PTCH1 to 
promote HH signaling during development (39-42). Notably, removal of all three co-
receptors resulted in the complete disruption of HH-mediated neural tube patterning, 
despite the presence of PTCH1, indicating the importance of these co-receptors in 
developmental processes (43). Thus, these co-receptors comprise a wider network of 
proteins required for HH pathway activation; their role in mediating HH signaling in adult 
tissues and disease, however, is still poorly understood.  
Hedgehog Signaling in Pancreatic Development 
Repression of HH signaling is required for proper pancreas development, as 
determined by experiments in chicks and mice.  Early ectopic expression of SHH driven 
by the Pdx1 promoter resulted in a small, poorly developed pancreas. Within the tissue, 
differentiated epithelial cells were present, but failed to organize properly, and mucinous 
lesions resembling the intestinal epithelium were present in the tissue rudiment. The 
surrounding mesenchyme was converted into smooth muscle cells resembling intestinal 
mesenchyme (44-46).  SHH expression at later developmental stages, after the onset of 
pancreas specification and morphogenesis, resulted in a decrease in both the exocrine 
and endocrine pancreatic epithelium, and an expansion of the mesenchyme (47). 
Expression of HH ligand in the fully developed pancreas, driven by the acinar cell 
specific Cela1 promoter, resulted in an expansion in mesenchymal cells; no defect was 
noted in the epithelial compartment aside from displacement of acinar cells due to the 
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expansion of pancreatic mesenchyme (48). While over-activation of HH pathway activity 
led to abnormal pancreatic development, pathway inhibition experiments resulted in an 
expansion of pancreatic tissue.  In chick embryos, SMO inhibition led to ectopic 
pancreas formation (49), and mice lacking Shh had a significant increase in pancreatic 
mass and endocrine cells relative to body size (50).   
Removal of Hhip, a HH pathway inhibitor, also resulted in impaired pancreatic 
morphogenesis and reduced tissue mass. Interestingly, acinar cell differentiation was 
not impeded; rather, the endocrine cells were reduced in number (51). Taken together, 
these studies support the role of HH as a negative regulator of pancreatic development, 
and they point at a critical dosage-dependent role of this signaling pathway, as even a 
minor perturbation in the pathway leads to impaired pancreatic development. 
Hedgehog Signaling in Pancreatitis 
Several studies have reported increased SHH expression in the epithelium of 
human patients with chronic pancreatitis, thus providing a descriptive link between 
ligand expression in chronic inflammation and neoplasia (52,53). However, the 
functional consequences of HH ligand expression during inflammation remain to be 
elucidated in mouse models.   
In the normal adult pancreas, all three HH ligands are undetectable, but pathway 
effectors, such as GAS1 and GLI1 are expressed in a subset of the stromal cells 
(46,54,55) (Figure 1.2), and HHIP expression is observed in islets (51). Lack of active 
HH signaling is not unexpected, as this is typically restricted to adult epithelium tissues 
with high turnover, such as the gut and skin (for review, see (56)).  Although active 
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Hedgehog pathway activity is quiescent in the pancreas during development and 
homeostasis, accumulating evidence indicates that it is essential for pancreatic recovery 
following tissue damage (51,54,57).  
Hedgehog Signaling in Pancreatic Cancer 
The first description of aberrant HH secretion in pancreatic cancer was provided 
by two studies (46,58). Although initially autocrine signaling was proposed, later studies 
indicated that HH ligands did not stimulate the tumor cells that secreted them. HH 
response was instead detected in stromal cells within the tumors. Administration of the 
SMO inhibitor cyclopamine to subcutaneously injected tumors reduced tumor growth 
compared to vehicle-treated cohorts (59). This effect was linked to HH-response of the 
infiltrating fibroblasts, as Smo deletion in fibroblasts significantly reduced their ability to 
promote tumor growth compared to their HH-responsive counterparts (59). Thus, 
canonical signaling in pancreatic tumors occurred in a paracrine manner, and the HH-
responsiveness of fibroblasts was associated with their ability to promote tumor growth. 
Evidence linking HH signaling to desmoplasia was demonstrated using a transformed 
epithelial cell line (T-HPNE) experimentally induced to overexpress SHH (T-
HPNE.SHH). Orthotopic injection of T-HPNE.SHH cells resulted in a significant increase 
of SMA+ myofibroblasts and ECM components compared to tumors from T-HPNE cells 
(60).  Taken together, these data supported a model wherein tumor-derived HH 
promoted the expansion of activated fibroblasts and desmoplasia that in turn promoted 
tumor growth (Figure 1.3). 
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The notion that HH signaling acts in a paracrine manner in pancreatic cancer 
was furthered by two studies demonstrating that autocrine HH activation is dispensable 
in the pancreatic epithelium. The first implemented a conditional deletion of Smo in the 
pancreatic epithelium, thus disabling canonical activation of the pathway in these cells. 
Deletion of Smo did not affect KRASG12D mediated tumorigenesis (61).  In a 
complementary experiment, a constitutively active form of SMO (SMOM2), first 
identified in basal cell carcinoma, was conditionally expressed in the pancreatic 
epithelium. Even the addition of KrasG12D did not accelerate tumorigenesis compared to 
epithelium harboring only KrasG12D (62). Thus, autocrine HH signaling in epithelial cells 
does not appear to play a role in pancreatic carcinogenesis.   
An intriguing finding was that cell-autonomous activation of Hedgehog signaling 
in the epithelium was compatible with normal pancreas development in contrast with 
ligand overexpression studies. This was shown using mice with either constitutively 
active SMO or a dominant active form of Gli2 in the epithelium (27,62). In the context of 
dominant active Gli2, the primary cilia was found to regulate activation of HH signaling; 
with intact cilia, mice with a dominant active form of Gli2 still could not efficiently activate 
the pathway. However, upon the ablation of primary cilia, HH activation of the pathway 
was observed in the epithelium leading to loss of both endocrine and exocrine tissue 
and expansion of pancreatic progenitor cells (63). Whether the cilia plays a regulatory 
role in pancreatic cancer has yet to be explored, although counterintuitively, the 
presence of primary cilia in pancreatic cancer was correlated with poorer overall survival 
in human patients (64).  
Epithelial Gli1 in Pancreatic Cancer. 
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Along with HH signaling to the surrounding stroma, non-canonical Gli1 
expression and activation in tumor cells has been described in human pancreatic 
cancer (46,58). Similarly, KPC mice have detectable Gli1 expression both in PanINs 
and in cancer cells, although to a much lower level than the surrounding stroma. 
Likewise, expression of GLI1 in human pancreatic cancer samples was significantly 
higher in the stroma compared to the epithelium (61,62). Unlike what was observed in 
stromal cells, Gli1 expression in the epithelium was not decreased when SMO was 
inactivated, indicating non-canonical regulation of its expression (61).  Ectopic 
expression of a dominant active form of GLI2 or GLI1 in the pancreatic epithelium did 
not induce PanIN formation, although GLI2 induced the formation of undifferentiated, 
sarcomatoid tumors (27). However, when combined with KRASG12D, both dominant 
active GLI2 and GLI1 accelerated PanIN formation (27,65). Conversely, in a mouse 
model of pancreatic cancer bearing a dominant repressor form of GLI3-which represses 
GLI1 and GLI2 mediated gene transcription in epithelial cells- KRASG12D-driven PanIN 
formation was reduced, whereas survival was prolonged (65).  While the effects of GLI1 
activation in the epithelium are not completely understood, some indication as to the 
mechanism of activation derives from in vitro studies that linked TGFβ signaling and 
NFκB signaling to GLI1 (52,61,66). 
Therapeutic Implications of Hedgehog Signaling in Cancer 
Clinical Modes of HH Pathway Inhibition 
The involvement of HH signaling in multiple malignancies, including basal cell 
carcinomas and medulloblastomas, as well as several gastrointestinal cancers, 
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underscores the clinical importance of Hedgehog pathway antagonists.  The most 
widely used HH antagonists in the clinic target SMO, thus preventing all downstream 
signaling.  Cyclopamine, a natural compound present in the corn lily, was the first 
identified SMO antagonist (67,68), and can inhibit HH signaling in mouse cells at an IC50 
= 300 nM (68). Cyclopamine is not suitable for clinical use due to its poor 
pharmacokinetics, including structural complexity, instability in acid and poor aqueous 
solubility (69), although it still retains widespread use in preclinical experiments. 
However, alternate compounds have been commercially synthesized that improve the 
bioavailability and pharmacokinetic properties of cyclopamine, including GDC-0449 and 
IPI-926 (70,71).   
Genentech: GDC-0449, also referred to as Vismodegib or Erivedge, was the first 
SMO inhibitor to pass phase II clinical trials, and is currently approved for treatment of 
locally advanced or metastatic basal cell carcinomas (BCC). In preclinical data, GDC-
0449 inhibited GLI1 expression in 10T1/2 embryonic fibroblasts at an IC50  = 13nM 
(71). A pilot study of GDC-0449 in a single patient with metastatic medulloblastoma 
resulted in a dramatic, although transient, reduction in tumor burden; rapid relapse was 
due to the selection of a SMO variant (D473H) resistant to inhibition (72,73). Currently, 
the National Cancer Institute has sponsored Phase I clinical trials to test the efficacy of 
GDC-0449 in children with medulloblastoma (NCT00822458). In pancreatic cancer, 
while early studies combining chemotherapy (gemcitabine) and GDC-0449 did not 
demonstrate clinical utility (74), additional trials in pancreatic cancer, along with other 
solid tumors, are in progress (NCT01088815, NCT01064622).   
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Infinity Pharmaceuticals: IPI-926, also known as Saridegib, is a semisynthetic 
analog of cyclopamine. It is still an investigational drug and is not currently approved for 
use by the FDA (70), although it has demonstrated potency in preclinical experiments 
using mouse models of medulloblastoma (75). In vitro, IPI-926 could inhibit Gli1 
expression in 10T1/2 embryonic fibroblasts at an IC50 of 9 nM, and interestingly, was 
also effective against the D473H SMO mutant (IC50 = 244 nM) that conferred resistance 
to GDC-0449 (75). In a Phase I trial, IPI-926 was effective against BCC that had not 
been previously treated with GDC-0449; patients previously treated with GDC-0449 
showed little response to IPI-926, indicating some therapeutic overlap between the two 
agents, although the shared mechanism behind this resistance is unclear (76).  
In addition to the inhibitors described above, alternative HH-antagonists have 
been synthesized by other companies including Novartis 
(LDE225/Erismodegib/Odozmo) (77), Bristol-Myers Squibb (BMS-833923/XL139)(78) 
and Pfizer (PF-04449913/Glasdegib) (79) and are also in clinical trials. Given the 
potential of HH inhibitors to treat HH-dysregulated cancers and the recurring issue of 
drug-resistance, the continued development of multiple HH inhibitors is clinically 
important.   
HH Pathway Inhibition in Pancreatic Cancer 
As a preclinical study of HH signaling inhibition in pancreatic cancer, tumor-
bearing KPC mice were treated with gemcitabine and the HH inhibitor IPI-926.  Either 
gemcitabine or IPI-926 had little effect when used as single agent. However, in 
combination, they conferred a survival benefit (19).  This effect was attributed to 
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improved perfusion of the tumors, due to an increase in vascularization, which was the 
result of a reduction of the stromal fibroblast population and of the accumulation of 
extracellular matrix.  These and other results indicating the benefits of targeting the 
stroma through HH inhibition led to clinical trials in human pancreatic cancer patients 
(NCT01130142).  However, in late 2013, these trials were terminated as patients 
treated with both HH inhibition and chemotherapy had faster disease progression than 
those on chemotherapy alone (80). Clinical trials of another HH inhibitor GDC-0449 
(Genentech) combined with gemcitabine in pancreatic cancer did not improve outcome 
compared to gemcitabine alone (74).  
In the wake of the disappointing clinical trials, several studies emerged that 
added complexity to the role of HH signaling in pancreatic cancer. First, the duration of 
HH inhibition was found to affect cancer progression.  While short-term inhibition of HH 
signaling in KPC mice with IPI-926 resulted in increased intratumoral vasculature and 
better drug perfusion (19), long-term treatment of KPC mice, starting at the PanIN 
stage, resulted in poorer survival (81). GDC-0449 administration also accelerated PanIN 
progression and tumor burden in KPC mice (82). Similarly, genetic deletion of Shh from 
the epithelium of KPC mice resulted in accelerated tumor progression and lethality 
(81,82). Intriguingly, while a similar experimental scheme was implemented in the two 
studies, the results are only partially overlapping. While both studies found reduced 
survival in mice lacking epithelial SHH, the nature of the tumors that formed was 
different.  In one case (81), instead of a classic presentation of pancreatic cancer, with 
duct-like structures surrounded by abundant stroma, deletion of SHH resulted in tumors 
reminiscent of sarcomatoid tumors in a subset of human patients.  In the second study 
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(82), the tumors had abundant stroma, although a mild reduction in this compartment 
was observed. Interestingly, the sarcomatoid tumors in KPC;Shhf/f were highly 
vascularized, which sensitized them to antivascular agents, which are typically 
ineffective in pancreatic cancer (83). 
Taken together, interpreting the results from these different studies is difficult, but 
some speculations can be made.  Shh deletion in the pancreas epithelium resulted in a 
compensatory upregulation of Ihh (81). Thus, it is possible that the end result of Shh 
depletion is a reduction, rather than complete ablation, of HH signaling in the pancreas. 
Many studies link reduced HH signaling to increased vascularization (19,55,81). While 
increased tumor vasculature might allow better drug perfusion, pancreatic cancer cells 
have a high propensity to develop resistance to gemcitabine. Thus, the end result of 
increasing the tumor vasculature might be to promote tumor growth.   
The Microenvironment of Pancreatic Cancer   
Despite the clinical inefficacy thus far of targeting the Hh pathway in pancreatic 
cancer, the microenvironment contains multiple cell types and signaling pathways that 
collectively influence tumorigenesis.   The manner in which these stromal components 
act upon each other and upon tumors cells is an area of active investigation.  
Macrophages 
Macrophages are a prominent population in the stroma of both human and 
mouse pancreatic cancers (84,85). In mice, macrophages are the dominant population 
of leukocytes present in the stroma.  These cells start accumulating in the pancreas 
during the PanIN stage, and persist throughout tumorigenesis (85).  
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Macrophages are highly plastic cells than can further polarize into a classically 
activated subtype or an alternatively activated subtype; each is associated with a 
particular cytokine and chemokine profile. Classically activated macrophages, also 
termed M1 macrophages, are typically associated with anti-tumor behavior, and express 
markers including iNOS and CD11c (86,87). Alternatively activated macrophages, also 
referred to as M2 macrophages, are thought to promote tumor growth, and express 
CD206 and Arg1, among others (88,89). In human pancreatic cancer, alternatively 
activated macrophages are prevalent in the tumor stroma (90). Moreover, their 
increased infiltration in human pancreatic cancer was associated with a poorer 
prognosis (90), and was also shown to promote epithelial-to-mesenchymal transition 
(EMT) of pancreatic cancer cells in vitro (88).  In mice, blockade of macrophage growth 
factor CSF1 (M-CSF) slowed tumor growth by enhancing the infiltration of cytotoxic T 
cells, which are normally excluded from the microenvironment, and thus cannot employ 
their anti-tumor function (91). Interestingly, CSF1 blockade specifically depleted the 
CD206+ population of cells, supporting the accumulating evidence that alternatively 
activated macrophages generally act to promote tumor growth. 
Mesenchymal Stem Cells 
The fibroblast population itself is heterogeneous and comprised of ill-defined 
subtypes (92). Unlike immune cells, which have better defined subtypes and tools with 
which to identify and study them, fibroblasts do not. Few surface markers exist to 
separate fibroblast populations, and thus they are often treated experimentally as a 
homogenous group of cells. Recently however, a fibroblast-like cell has been identified 
in the stroma of several solid, epithelial tumors – the Mesenchymal Stem Cell (MSC).  
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While macrophages have been described in the pancreatic cancer stroma, the presence 
and activity of MSCs has not, although they have been noted in the normal pancreas 
(93). MSCs are multipotent cells capable of differentiating into osteoblasts, 
chondrocytes, and adipocytes. Aside from their hallmark multipotency, MSCs can be 
identified by a panel of cell surface markers, namely CD44+/CD49a+/CD73+/CD90+, and 
negative for markers of hematopoietic and endothelial lineages (94).  
  Originally discovered in the bone marrow (95), these cells are now thought to 
reside in virtually all adult organs, including the pancreas (96). Functional studies have 
described MSCs as ‘medicinal signaling cells’ due to their ability to both stimulate 
epithelial cell growth after injury and modulate the immune system (97-99). MSCs were 
also found to play an active role in tumor growth in a context-dependent manner. In 
breast carcinoma, MSCs significantly increased cancer cell metastasis via CCL5 
expression upon co-injection with cancer cells into mice (100).  A study in ovarian 
carcinoma found that stromal MSCs supported tumor growth by secretion of BMP 
pathway proteins (101). More recently, a study on stromal MSCs in lymphomas found 
that MSC tumor promotion was abrogated upon depletion of macrophages, although the 
requirement of a particular subset of macrophages was not determined (102). 
Regardless of the specific mechanism, these studies clearly show that MSCs affect 
tumorigenesis and are thus an important component of the tumor microenvironment. 
Moreover, notwithstanding the extensive desmoplastic reaction in pancreatic cancer, 
interaction between stromal cell populations remains largely unexplored.   
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Dissertation Overview 
In this dissertation, I explore multiple aspects of the role of the microenvironment 
in pancreatic cancer pathogenesis. In Chapter Two, HH co-receptors BOC, CDON, and 
GAS1, whose function in pancreatic cancer is unknown, are evaluated for their role in 
promoting tumor growth.  While combined Hedgehog inhibition and chemotherapy has 
shown promise in preclinical models of pancreatic cancer (19), human clinical trials 
have been disappointing (74,80). Moreover, even when HH pathway inhibition through 
SMO antagonism is effective in cancer, the development of drug-resistance is an issue 
(72,73); thus multiple modes to inhibit the HH pathway aside from SMO inhibition are 
clinically valuable. In Chapter Two, which has been published (55), I find that GAS1, 
BOC, and CDON are expressed in fibroblasts in the reactive stroma of pancreatic 
cancer, the predominant cell population responding to tumor-derived HH.  Further, 
through use of mouse models with genetic deletions of these co-receptors, I identify a 
previously unappreciated dosage-dependent role for HH signaling in pancreatic tumor 
growth.   
In Chapter Three, which has also been published (54), I focus on the role of HH 
signaling in pancreatitis and recovery. Tissue recovery is a complex process that 
involves crosstalk between the damaged epithelium and surrounding cells, such as 
fibroblasts and immune cells (for review, see (103) or (104)). In pancreatitis, further 
understanding the molecular mechanisms behind tissue damage and repair are 
important given that pancreatitis is a risk factor for cancer and no specific treatment 
exists for it. While SHH expression has been described in human pancreatitis (52,53), 
its functional consequences remain to be explored experimentally. In Chapter Three, I 
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focus on understanding the role of Hedgehog signaling in pancreatic repair, using two 
modes of injury: caerulein-induced pancreatitis, and KrasG12D inactivation. Mice lacking 
a copy of Gli1 or mice treated with a HH inhibitor are unable to properly remodel the 
injury-induced fibroinflammatory stroma; this impaired repair process is specifically 
linked to impaired secretion of immunomodulating cytokines from pancreatic fibroblasts, 
indicating a role for HH signaling in fibroblast-immune cell crosstalk during pancreas 
recovery.   
Further insight into the heterogeneity of the microenvironment is explored in 
Chapter Four. Unlike immune cells, fibroblasts do not have panels of cell-surface 
markers and experimental tools with which to identify and study subsets within this 
population of cells. Thus, although fibroblast heterogeneity within the cancer 
microenvironment has been acknowledged (92,105), fibroblasts are still typically treated 
as a homogenous population of cells. In Chapter Four, I identify a subset of fibroblast-
like cells in the pancreas – the MSC - and describe their ability to promote tumor 
growth. Tumor-derived MSCs depend on macrophages to promote tumor growth, and 
can direct the polarization of alternatively activated macrophages, thereby impacting 
tumor growth. Finally, in Chapter Five, further questions and directions identified by this 
dissertation work will be discussed. 
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Figures 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1: HH signaling  
In the absence of HH ligand, PTCH1 inhibits SMO. Upon binding of HH ligand to 
PTCH1, its inhibitory function ceases and SMO then can initiate HH signaling, 
culminating in the activation of the GLI family of transcription factors.  In addition to 
PTCH1, co-receptors BOC, CDON, and GAS1 can also bind HH ligand and activate 
HH signaling. 
(cartoon credit: Dr. Ben Allen) 
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Figure 1.2: HH pathway components Gli1 and Gas1 are expressed 
in the pancreas.  In the pancreas of untreated Gli1Lacz/+ or Gas1τLacZ/+ 
mice, GLI1 and GAS1 are expressed in a perivascular and periductal 
manner (left). Asterisks (*) marks ducts and black arrows mark blood 
vessels. Scale bar 20μm.  Analysis of neoplastic pancreas from 
KC;Gli1LacZ/+ or KC;Gas1τLacZ/+ shows that during tumorigenesis, GLI1 
and GAS1 are expressed throughout the accumulating reactive stroma 
(right). Scale bar 50μm 
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Figure 1.3: Paracrine HH signaling in pancreatic cancer. 
In pancreatic cancer, HH ligand from tumor cells activate the pathway in 
surrounding fibroblasts, which in turn signal back to the tumor; the 
nature of this response is poorly understood.  
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CHAPTER TWO 
Dosage-Dependent Regulation of Pancreatic Cancer Growth and Angiogenesis by 
Hedgehog Signaling1  
 
Abstract 
Pancreatic cancer, a hypovascular and highly desmoplastic cancer, is 
characterized by tumor expression of Hedgehog (HH) ligands that signal to fibroblasts in 
the surrounding stroma, which in turn promote tumor survival and growth. However, the 
mechanisms and consequences of stromal HH pathway activation are not well 
understood. Here we show that the HH co-receptors GAS1, BOC, and CDON are 
expressed in cancer-associated fibroblasts. Deletion of two co-receptors (Gas1 and 
Boc) in fibroblasts reduces HH-responsiveness. Strikingly, these fibroblasts promote 
greater tumor growth in vivo that correlates with increased tumor-associated vascularity. 
In contrast, deletion of all three co-receptors (Gas1, Boc and Cdon) results in the near 
complete abrogation of HH signaling and a corresponding failure to promote 
tumorigenesis and angiogenesis. Collectively, these data identify a novel role for HH-
                                                          
1 Originally published as: Mathew, E., Zhang, Y., Holtz, A. M., Kane, K. T., Song, J. Y., 
Allen, B. L., and Pasca di Magliano, M. (2014) Dosage-dependent regulation of 
pancreatic cancer growth and angiogenesis by hedgehog signaling. Cell Rep 9, 484-
494 (doi:10.1016/j.celrep.2014.09.010) 
34 
 
dosage in pancreatic cancer promotion and may explain the clinical failure of HH 
pathway blockade as a therapeutic approach in pancreatic cancer. 
 
Introduction 
Pancreatic cancer, one of the deadliest human malignancies, is almost invariably 
associated with oncogenic mutations of Kras and the inappropriate activation of 
embryonic signaling pathways (1,2). Pancreatic cancer is preceded by precursor 
lesions, the most common of which are Pancreatic Intraepithelial Neoplasias (PanINs) 
(3). Notably, tissue-specific expression of mutant Kras in mice recapitulates the step-
wise progression of the human disease and constitutes a reasonable mouse model of 
pancreatic cancer (4). 
Aberrant activation of Hedgehog (HH) signaling is observed in pancreatic cancer 
in both humans (5,6) and mice (7). In pancreatic cancer, the HH pathway is proposed to 
act in a paracrine manner, where epithelial tumor cells secrete HH ligands that signal to 
cells of the tumor stroma (8). HH signaling is activated by ligand binding to the twelve-
pass transmembrane protein Patched (PTCH1), which relieves an inhibitory effect on a 
second, GPCR-like protein, Smoothened (SMO) (9).  De-repression of SMO results in a 
cascade of events that ultimately leads to the activation of GLI transcription factors and 
modulated target gene expression.  HH pathway genes such as PTCH1 and GLI1 are 
direct transcriptional targets, thus establishing a feedback loop that regulates the level 
of pathway activity (10,11).  
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In tumors classically associated with cell-autonomous activation of HH signaling, 
such as basal cell carcinoma and medulloblastoma, HH inhibition has emerged as a 
therapeutic strategy (12,13). Small molecule inhibitors that target SMO have been 
successfully developed to inhibit signaling and induce tumor regression (13). HH 
inhibitors have also been applied to tumor types that rely on paracrine HH signaling (8). 
While SMO inhibition in the clinic has met with initial success, the emergence of drug-
resistant SMO mutations in tumors (14) underscores the need for alternative 
approaches to restrict HH pathway function. 
GAS1, BOC and CDON are cell surface-associated proteins that bind HH ligands and 
function as pathway activators (15-18). During neural tube development, GAS1, BOC 
and CDON are required for HH signal transduction (19). However, despite their 
collective requirement during HH-dependent embryogenesis, the role of these proteins 
has not been explored in adult tissues and organs, and their potential contribution to 
disease, including cancer, is currently unknown.  
Here, we investigated GAS1, BOC and CDON expression and function in 
pancreatic cancer to determine whether they constitute potential novel therapeutic 
targets. We found that all three co-receptors were expressed in the adult pancreas and 
upregulated in pancreatic cancer stroma. We also observed that, similar to their role in 
embryogenesis, these co-receptors were required to mediate HH signal transduction in 
pancreatic fibroblasts. Counter to prevailing paradigms, while deletion of two co-
receptors (Gas1 and Boc) in pancreatic fibroblasts led to reduced HH-responsiveness, 
this resulted in increased tumor growth. In contrast, deletion of all three co-receptors 
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(Gas1, Boc and Cdon) abrogated HH signaling and blocked tumor promotion. Notably, 
the tumor promoting effects of reduced HH signaling were due to increased 
angiogenesis mediated by the tumor stroma. These findings uncover a novel dosage-
dependent role of HH signaling in the regulation of tumor angiogenesis in pancreatic 
cancer.  
Materials and Methods 
Mice 
Mice were housed in specific pathogen-free facilities of the University of Michigan 
Comprehensive Cancer Center. This study was approved by the University of Michigan 
University Committee on Use and Care of Animals (UCUCA) guidelines. Ptf1a-Cre mice 
(20) were intercrossed with LSL-KrasG12D (4) to generate Ptf1a-Cre;LSL-KrasG12D (KC) 
animals. KC mutant mice were further crossed with mice bearing reporter alleles 
Gas1LacZ/+ (16) or BocAP/+ (21) to generate KC;Gas1LacZ/+ or KC;BocAP/+.  Acute 
pancreatitis was induced by two 8-hourly series of intraperitoneal injections with 
caerulein (Sigma) at a concentration of 75ug/kg over a 48-hour period, as previously 
described (22).  
Cell Culture 
Primary mouse pancreatic fibroblast lines were derived from E18.5 wildtype or Gas1-/-
;Boc-/- pancreata. Embryonic pancreas were minced via vigorous pipetting then 
immediately plated. MEFs were isolated and established using the methods of Todaro 
and Green (23). Samples were cultured in IMDM supplemented with 10% FBS and 1% 
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penicillin/streptomycin (Gibco). For HH signaling assays, plated cells were serum-
starved (IMDM supplemented with 0.5% serum) for 36h prior to addition of conditioned 
media, and samples collected at indicated timepoints.   
Immunohistochemistry/Immunofluorescence 
Histology and immunohistochemistry/immunofluorescence stainings were performed as 
previously described (24). Primary antibodies used were β-Gal (1:200, Abcam), CD45 
(1:200, BDPharm), CD31 (1:100, BDPharm), Ki67 (1:100, Vector Laboratories), αSMA 
(1:1000, Sigma), E-cadherin (1:100, Cell Signaling), Vimentin (1:100, Cell Signaling), 
and Cleaved Caspase-3 (Cell Signaling). Images from immunohistochemical stains 
were obtained with an Olympus BX-51 microscope, Olympus DP71 digital camera, and 
CellSens standard v1.6 software. For immunofluorescence, Alexa Fluor (Invitrogen) 
secondary antibodies were used. DAPI (Invitrogen) was used to counterstain cell nuclei. 
Images from immunofluorescence stains were obtained using an Olympus IX-71 
confocal microscope and FluoView FV500/IX software. 
RT-qPCR 
Tissue for RNA extraction was prepared through overnight incubation in RNAlater-ICE 
(Ambion) at -20oC, then isolated using RNeasy Protect (Qiagen) according the 
manufacturer’s instructions.  Reverse transcription reactions were conducted using a 
High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems). Samples for RT-
qPCR were prepared with 1x SYBR Green PCR Master Mix (Applied Biosystems) and 
primers: Gli1, 5´-tggactctcttgacctggacaac-3´ (forward) and 5´-ggccctgggcctcatc-
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3´(reverse); Ptch1, 5´- ttgtggaagccacagaaaacc -3´ (forward) and 5´- 
tgtctggagtccggatgga -3´(reverse); Gapdh was used as the housekeeping gene 
expression control. All primers were optimized for amplification under reaction 
conditions as follows: 95°C 10 minutes, followed by 40 cycles of 95°C 15 seconds and 
60°C 1 minute. All samples underwent melt curve analysis following the amplification 
protocol.  
Subcutaneous Tumor Models 
5 x 105 tumor cells were injected alone or in combination with an equal number of 
fibroblasts into the flanks of CB17/SCID mice (Charles River, stock/strain #236) at a 1:1 
ratio of complete medium and Matrigel (BD Biosciences #356234). Tumor size was 
measured weekly by caliper. 
Chick Chorioallantoic Membrane (CAM) Assay 
The CAM assay was performed as described previously (25). Briefly, 3 x 105 tumor cells 
were seeded alone or with an equal number of fibroblasts atop the CAM of E11.5 
fertilized eggs. After three days of incubation at 37°C, the tumor cells and surrounding 
CAM were dissected, fixed in 4% paraformaldehyde and imaged with a Nikon SMZ1500 
Scope and NIS-Elements D Imaging software. 
Statistical Analysis 
The data is expressed as the mean ± SEM. One-way ANOVA with a Tukey post-test 
and Student’s t-tests were used to compare data. A p value <0.05 was considered 
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statistically significant. Significance values indicated by asterisks are as follows: 
*p<0.05, **p < 0.01, ***p < 0.0005, ****p < 0.0001 
Results 
GAS1, BOC, and CDON are Expressed in Fibroblasts and Stellate Cells in the Normal 
Adult and Neoplastic Pancreas. 
Given the requirement of the HH co-receptors GAS1, BOC and CDON in 
embryonic development (19), we sought to identify a role for these HH pathway 
components in adult tissue. To determine if GAS1, BOC and CDON were expressed in 
the normal pancreas, during pancreatitis, and/or in the neoplastic pancreas, we 
harvested pancreata from adult wildtype or Ptf1aCre;LSL-KrasG12D (KC) mice (4).  KC 
pancreata were harvested three weeks following the induction of acute pancreatitis 
using the CCK agonist caerulein; this treatment synergizes with oncogenic Kras to drive 
tissue-wide PanIN formation and the accumulation of a fibroinflammatory stroma 
(22,26). Wildtype pancreata were harvested from either untreated adult animals or from 
animals one day after caerulein treatment, at the peak of pancreatitis. Expression of all 
three co-receptors, as measured by RT-qPCR analysis, was barely detectable in control 
tissue (untreated adult pancreata), but was significantly increased in KC pancreata. In 
addition, we observed a significant increase in Boc expression and a modest increase in 
Gas1 and Cdon expression in the pancreatitis samples (Figure 2.1A).   
To determine the cellular compartment in which these co-receptors are 
expressed, we crossed mice bearing reporter alleles of Gas1 (Gas1LacZ/+; (16)) or Boc 
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(BocPLAP/+; (21)) into the KC model of pancreatic cancer (Figure 2.1B). Pancreata were 
harvested from adult animals three weeks after inducing acute pancreatitis. Analysis of 
control pancreata revealed a perivascular and periductal expression pattern for Gas1 
and Boc, as well as in scattered cells throughout the parenchyma (Figure 2.1B). 
Strikingly, in KC tissues, Gas1 and Boc expression expanded throughout the stroma 
surrounding PanIN lesions (Figure 2.1B). 
To confirm that the RT-qPCR and reporter allele expression data correlated with 
increased co-receptor protein levels, we performed antibody detection of GAS1, BOC 
and CDON in pancreatic tissue (Figure 2.2). Consistent with our gene expression data, 
we detected limited stromal expression of GAS1, BOC and CDON in the normal 
pancreas (Figure 2.2A), and increased co-receptor expression in the stroma 
surrounding PanIN lesions and tumor cells in KC and KPC mice (Figures 2.2B and 
2.2C). These data suggest that GAS1, BOC and CDON are expressed in a population 
of stromal cells in the adult pancreas that expands during PanIN formation.  
To identify the specific cell type within the stroma expressing these co-receptors, 
we performed antibody staining of tissue from PanIN-bearing KC;Gas1LacZ/+ pancreata 
(Figures 2.3 and 2.4). Gas1LacZ expression was excluded from epithelial (E-cadherin+) 
and hematopoeitic (CD45+) cells (Figure 2.3A, white arrows). Similarly, β-
galactosidase (β-gal) was not detected in endothelial cells lining the blood vessels 
(Figure 2.3B). In contrast, we detected widespread co-expression of β-gal with smooth 
muscle actin (SMA), a marker of activated fibroblasts (Figure 2.3C, yellow arrows), 
throughout the stroma, except immediately surrounding blood vessels (Fig. 2.1E). Gas1 
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expression in fibroblasts was confirmed by co-staining with antibodies directed against 
β-gal and Vimentin (Figure 2.3D, yellow arrows), another fibroblast marker (27). We 
also performed antibody staining of tissue from PanIN-bearing KC;BocPLAP/+ pancreata 
(Figure 2.5). Antibody detection of alkaline phosphatase (AP) co-localized with SMA 
(Figure 2.5A), suggesting that Gas1 and Boc were co-expressed in a population of 
fibroblasts in the pancreas. In contrast, no co-localization was observed of AP with 
either E-cadherin (Figure 2.5B) or CK19 (Figure 2.5C), both epithelial markers. Thus, 
Boc expression was confined to the mesenchymal compartment. Finally, we performed 
RT-qPCR analysis of primary mouse pancreatic tumor cells, fibroblasts, and flow-sorted 
macrophages from the Pft1a-Cre;LSL-KrasG12D;p53R172H/+(KPC) (7) and iKras (24) 
pancreatic cancer models. We detected expression of Sonic HH ligand (Shh) only in the 
tumor cells (Figure 2.6A), whereas only fibroblasts expressed Gas1 (Figure 2.6B). 
Macrophages, another prominent stromal cell population did not express Shh or Gas1 
(Figures 2.6A and 2.6B).  
Two alternative models could explain the increase in Gas1, Cdon and Boc 
expression in the neoplastic pancreas– increased expression on a per cell basis, or 
increased expression due to increased numbers of fibroblasts expressing these co-
receptors. To distinguish between these two possibilities, we normalized the expression 
of the co-receptors to the mesenchymal marker Vimentin. Using this approach, we 
observed no change in Gas1, Cdon and Boc expression in the neoplastic pancreas 
compared to control (Figure 2.6C). Thus, the increase in co-receptor expression is 
caused by an increase in the number of co-receptor expressing cells within the tissue.  
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To determine whether our findings were relevant to human samples, we 
performed RT-qPCR on resected human pancreatic cancer samples and adjacent 
uninvolved pancreas. Upregulation of all three co-receptors was detected in the tumor 
samples (Figure 2.7A).  To determine which compartment expressed the co-receptors, 
we obtained RNA from primary human tumor cells and primary human cancer 
associated fibroblasts (CAFs).  We found elevated co-receptor expression in the CAF 
population, but not in the tumor cells (Figure 2.7B). As expected, VIMENTIN and E-
CADHERIN were restricted to the CAF and tumor compartments respectively, thus 
confirming the identity of the samples (Figure 2.7C). These data suggest that 
upregulation of HH co-receptors is a phenomenon observed in human pancreatic 
cancer and recapitulated in mouse models of this disease.  
Together, these data demonstrate that Gas1, Boc, and, Cdon are expressed in 
fibroblasts in both normal and PanIN-bearing pancreata and that their expression 
increases during pancreatic tumorigenesis as activated fibroblasts accumulate in the 
pancreas. Notably, this expression pattern resembles that observed for Ptch1 in KC 
mice (28), thus placing these co-receptors in the same cell population previously 
reported to respond to HH signaling in pancreatic cancer.  
GAS1 and BOC Mediate HH-responsiveness in Pancreatic Fibroblasts 
GAS1, BOC and CDON promote HH signaling in the developing neural tube in a 
ligand-dependent manner (19). To determine whether these co-receptors are required 
to transduce HH signals in fibroblasts, we generated wildtype and Gas1-/-;Boc-/- mouse 
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embryonic fibroblasts (MEFs) and treated them with control or SHH conditioned 
medium. The cells were harvested 48 hours after treatment and analyzed for HH target 
gene expression (Gli1 and Ptch1). We found significantly attenuated, although 
measurable levels of Gli1 and Ptch1 expression in SHH-CM treated Gas1-/-;Boc -/- MEFs 
compared to wildtype MEFs (Figure 2.8A).  
Activation of HH signaling in fibroblasts has been reported to promote tumor 
growth in co-transplantation experiments (8). Thus, we predicted that Gas1-/-;Boc-/- 
MEFs would display reduced tumor-promoting ability compared to wildtype MEFs. To 
test this hypothesis, we co-injected the human pancreatic cancer cell lines Hs766T and 
MiaPaCa with either wildtype or Gas1-/-;Boc-/- MEFs in immune compromised mice (for 
schematic, see Figure 2.8B). Surprisingly, tumor cells co-injected with Gas1-/-;Boc-/- 
MEFs grew significantly larger than tumor cells injected alone or co-injected with 
wildtype MEFs (Figures 2.8C and 2.8D). Analysis of these tumors revealed comparable 
epithelial histology for all experimental cohorts, including the accumulation of a 
collagen-rich stroma (Figure 2.9A). However, blood vessel density was dramatically 
increased in tumors co-injected with Gas1-/-;Boc-/- MEFs compared to tumor cells alone 
or co-injected with wildtype MEFs (Figures 2.9A and 2.9B).  
To study this phenomenon in a more physiologically relevant system, we 
replaced MEFs with primary pancreatic fibroblasts isolated from either wildtype or Gas1-
/-;Boc-/- E18.5 mouse embryos (Figure 2.10A). Despite the perinatal lethality of Gas1-/-
;Boc-/- embryos (19), histological analysis of E18.5 pancreata revealed no gross 
abnormalities (data not shown).  To assess HH-responsiveness, we treated wildtype 
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and Gas1-/-;Boc-/- pancreatic fibroblasts with control or SHH-conditioned media and 
extracted RNA 24 hours later. Similar to the MEF lines, SHH treatment induced robust 
expression of both Gli1 and Ptch1 in wildtype pancreatic fibroblasts, whereas this 
response was significantly attenuated in Gas1-/-;Boc-/- pancreatic fibroblasts (Figure 
2.10A). Thus, HH co-receptors are required for normal HH signaling in both MEFs and 
pancreatic fibroblasts.  
 We then repeated subcutaneous co-injection experiments of tumor cells and 
fibroblasts, this time using pancreatic fibroblasts instead of MEFs and primary human 
pancreatic tumor cells (1319; (29,30)) instead of human pancreatic tumor cell lines. 
1319 cells were injected alone or in combination with either genotype of pancreatic 
fibroblasts into mice. Notably, 1319 cells express SHH in culture at levels comparable to 
Hs766T cells (Figure 2.10B). Injection of 1319 cells alone formed subcutaneous tumors 
that were larger upon co-injection with wildtype fibroblasts, as expected (Figure 2.11A) 
(8). However, co-injection with Gas1-/-;Boc-/- pancreatic fibroblasts resulted in even 
larger tumors (Figure 2.11A). Tumor histology from each cohort was similar as 
assessed by H&E and Gomori staining, with a marked ductal morphology and abundant 
stroma, thus resembling the most common histology of human pancreatic cancer 
(Figure 2.11B) (31). However, CD31 immunostaining revealed a dramatic increase in 
vasculature within tumors co-injected with Gas1-/-;Boc-/- pancreatic fibroblasts (Figures 
2.11C and 2.11D). The Gas1-/-;Boc-/- fibroblasts were detected in close association with 
blood vessels, as determined by β-gal immunostaining (Figure 2.11D). Thus, stromal 
deletion of Gas1 and Boc, tested in both MEFs and pancreatic fibroblasts, results in 
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attenuated HH-responsiveness that paradoxically increases tumor growth. Given the 
heterogeneity of stromal fibroblasts (27), these Gas1 and Boc expressing fibroblasts 
may represent a subset of cells in which HH ligands inhibit an angiogenic response. 
Dosage-dependent Stromal HH Signaling Differentially Promotes Pancreatic Tumor 
Growth. 
Our data contrast with previous studies in which SMO blockade in the stroma 
inhibits pancreatic tumor growth (8,32). Notably, despite the significantly reduced 
response to HH signaling in Gas1-/-;Boc-/- fibroblasts, these cells are not completely 
refractory to HH pathway stimulation (Figure 2.8A and 2.10A). One possibility is that 
the level of HH pathway activation differentially affects pancreatic tumor growth.  
To understand the relationship between HH signaling dosage and tumor 
promotion, we tested Gas1-/-Boc-/-;Cdon-/- MEFs. Of note, we could not use pancreatic 
fibroblasts as triple null embryos die at E9.5 (19) at the onset of pancreas development. 
Gas1-/-Boc-/-;Cdon-/- MEFs had nearly undetectable activation of HH target genes when 
exposed to SHH conditioned medium (Figure 2.12A). We co-transplanted human 
pancreatic 1319 tumor cells alone, or with three different cohorts of MEFs: wildtype, 
Gas1-/-;Boc-/- and Gas1-/-Boc-/-;Cdon-/-  (see schematic in Figure 2.12B). Again, 
wildtype MEFs promoted tumor growth compared to tumor cells alone, and Gas1-/-;Boc-/- 
MEFs promoted tumor growth further (Figures 2.12C and 2.12D). In contrast, tumors 
co-injected with Gas1-/-;Boc-/-;Cdon-/- MEFs were comparable both in growth rate and 
size at dissection to tumor cells alone (Figure 2.12C and 2.12D). These data are 
46 
 
consistent with the reduced tumor-promoting ability of Smo-/- MEFs that are completely 
refractory to HH stimulation (8).  
Although tumor size varied between the different experimental groups, the 
histology was similar, with ductal structures surrounded by collagen rich stroma (Figure 
2.13A). Cell death was similar in all experimental cohorts (Figure 2.13B), however we 
detected increased intratumoral proliferation in co-injections with tumor cells and Gas1-/-
;Boc-/-  MEFs; this effect was abrogated in co-injections with Gas1-/-;Boc-/-;Cdon-/-  MEFs 
(Figure 2.13C).  
To verify that the co-injected MEFs persisted within the tumor at the time of 
analysis, we took advantage of lineage tracing provided by the expression of the β-gal 
reporter from the Gas1 locus in these cells.  By β-gal staining and quantitation we 
detected that both double and triple knock-out cells were present within the tumors 
(Figure 2.14A). Notably, the level of SHH ligand, produced by the tumor cells (detected 
with human-specific primers and normalized to human CYCLOPHILIN) did not change 
among the different groups (Figure 2.14B).  
 Genetic inactivation of Shh in multiple mouse models of pancreatic cancer 
resulted in variable reduction of stroma accumulation in different settings (33,34). To 
further investigate potential changes to the stroma in our model, we quantified the 
relative ratio of mesenchymal cells within the tumors (identified by immunostaining for 
Vimentin), and observed no measurable change (Figures 2.15A and 2.15B). 
Furthermore, RT-qPCR analysis for Collagen I revealed no difference among the 
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different cohorts (Figure 2.15C), indicating no changes in fibrosis. The differences 
between the two experimental groups might derive from the different timing of HH 
pathway alteration.  Interestingly, analysis of pre- and post-treatment biopsies of liver 
metastases in a recent clinical trial of the HH inhibitor GDC-0449 revealed only a mild 
reduction of fibrosis in half the patients, and no changes in fibrosis in the other half, 
consistent with our findings (Dr. Diane Simeone, University of Michigan, personal 
communication). 
While the accumulation of fibroblasts within the stroma did not change, the 
number of blood vessels was significantly increased in tumors co-injected with Gas1-/-
;Boc-/- MEFs but not in tumors co-injected with Gas1-/-;Boc-/-;Cdon-/- MEFs compared 
with control, as quantified by CD31 immunostaining (Figures 2.16A and 2.16B). A 
similar increase in vasculature was previously observed following genetic ablation of 
Shh or following drug-mediated inhibition of SMO, although the mechanism remained to 
be investigated (32-34). Thus, reduced HH response promotes tumor vascularity and 
growth, whereas complete HH pathway blockade fails to promote tumor vascularity  and 
growth.  
Reduced HH Signaling Promotes Angiogenesis. 
To determine the mechanism by which reduced HH signaling promotes tumor 
growth and vascularity, we measured the expression of several angiogenic factors by 
RT-qPCR (Figures 2.17A and 2.17B). Along with VEGFa, the angiopoietins (ANGPT1 
and ANGPT2) encompass a family of factors that act on the vascular endothelium (35). 
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In both Gas1-/-;Boc-/- MEFs and pancreatic fibroblasts, Angpt2 was upregulated 
compared to control pancreatic fibroblasts and MEFs respectively; in contrast, Angpt2 
expression in Gas1-/-;Boc-/-;Cdon-/- MEFs was comparable to wildtype MEFS (Figures 
2.17A and 2.17B). The expression of other angiogenic factors varied between MEFs 
and pancreatic fibroblasts, although in all cases, reduced HH signaling resulted in 
increased expression of angiogenic factors, while the abrogation of HH signaling 
inhibited angiogenic gene expression (Figures 2.17A and 2.17B). For example, Angpt1 
expression was significantly upregulated in Gas1-/-;Boc-/- pancreatic fibroblasts (Figure 
2.17A), while Vegfa , previously described as a HH target in stromal perivascular cells 
(36) was upregulated in Gas1-/-;Boc-/- MEFs (Figure 2.17B). The specific gene 
programs activated were not identical, possibly indicating distinct properties of 
fibroblasts of different origins.      
To determine whether the change in expression of the angiogenic factors 
depended on ligand-mediated HH signaling, we treated wildtype or Gas1-/-;Boc-/- 
pancreatic fibroblasts with control-conditioned medium or SHH-conditioned medium. 
SHH treatment induced expression of Vegfa and Angpt1, while repressing expression of 
Angpt2 (Figure 2.18A) consistent with previous publications (Lee et al., 2007; Zhang et 
al., 2011). The induction of Vegfa and overall expression levels were similar in Gas1-/-
;Boc-/- pancreatic fibroblasts. In contrast, both Angpt1 and Angpt2 had higher basal 
expression levels in Gas1-/-;Boc-/- pancreatic fibroblasts, but the extent of relative 
induction or repression in response to SHH was reduced compared to wildtype 
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fibroblasts, indicating that both ligand-dependent and ligand-independent mechanisms 
regulated the expression of these angiogenic factors (Figures 2.18A and 2.18B).     
To further dissect the angiogenic properties of fibroblasts lacking Gas1 and Boc, 
we used the chick chorioallantoic membrane (CAM) assay. Gas1-/-;Boc-/- pancreatic 
fibroblasts and MEFs implanted alone atop the CAM induced the formation of more 
blood vessels than wildtype MEFs. Notably, this pro-angiogenic effect was not detected 
in Gas1-/-;Boc-/-;Cdon-/- MEFs (Figure 2.18C).  
We next co-implanted human pancreatic 1319 tumor cells with wildtype or Gas1-/-
;Boc-/- pancreatic fibroblasts.  Wildtype fibroblasts promoted tumor growth in CAM 
assays, in agreement with our observations in the mouse (Figures 2.19A and 2.19B). 
Again, Gas1-/-;Boc-/- pancreatic fibroblasts promoted the growth of even larger, more 
vascularized tumors (Figures 2.19A and 2.19B). Similar results were obtained using a 
primary mouse pancreatic cancer cell line (30) derived from the KPC (7) pancreatic 
cancer model (Figure 2.19C).   
We then tested Gas1-/-;Boc-/-;Cdon-/- MEFs in this assay and observed reduced 
tumor growth and vascularization (Figures 2.19D and 2.19E), indicating that tumor 
promotion and angiogenesis are specifically linked to the degree of HH-responsiveness. 
Similar to the subcutaneous tumor injections, Gas1-/-;Boc-/-;Cdon-/- fibroblasts did not 
impact tumor growth compared to tumor cells alone (Figures 2.19D and 2.19E). 
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Discussion 
The Hedgehog co-receptors GAS1, BOC and CDON are required to mediate HH 
signaling during embryonic development (19), but their potential role in adult tissues and 
in disease remained largely unexplored. Here, we show that these co-receptors are 
expressed in pancreatic cancer (Figures 2.1 and 2.7) and modulate the levels of HH-
responsiveness in pancreatic fibroblasts (Figures 2.18A, 2.10A and 2.12A). Despite 
initial expectations that fibroblasts with reduced HH-responsiveness would be impaired 
in their ability to support tumor growth, surprisingly, we found that these cells promoted 
tumor growth to a significantly greater extent than wildtype fibroblasts (Figures 2.8 and 
2.11). Although HH pathway inhibition showed promise in mouse models of pancreatic 
cancer (32), clinical trials in humans were unsuccessful (37). Treatment with HH 
inhibitors in human patients are likely to result in a strong reduction, but not complete 
inactivation, of HH signaling, since the drugs are continuously metabolized and excreted 
in between doses. Here we show that HH dosage is a key consideration in cancer 
treatment, where reduced levels of HH signaling evoke a potent angiogenic response 
(Figure 2.20). Thus, an angiogenic response might constitute a clinical readout of 
successful, but partial, HH blockade in vivo. While dosage-specific HH response has not 
been considered in cancer, developmental biology provides ample evidence of HH 
target genes activated at specific thresholds of signaling (for review, see (38)). Further, 
although angiogenic blockade has not been used in pancreatic cancer due to its 
hypovascularity, our results raise the possibility that HH pathway blockade in pancreatic 
cancer may render tumors susceptible to anti-angiogenic therapy. A recent study 
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indicates a possible benefit of this combination therapy on a mesenchymal subtype of 
pancreatic cancer in genetically engineered mice (34). Whether the failure of the recent 
HH inhibition trials in pancreatic cancer are due to an increase in angiogenesis should 
be investigated.  
Another aspect of interest is the finding that MEFs and pancreatic fibroblasts 
have differences in HH-mediated gene regulation. The differences among fibroblasts 
populations in different organs are poorly understood, and might play an important role 
in cancer treatment, as fibroblasts at the metastatic sites might respond differently to 
treatment compared to fibroblasts at the primary site. HH signaling has been associated 
with pancreatic cancer metastasis (39), indicating the need for further studies aimed at 
characterizing HH response in fibroblasts derived from the pancreas and from common 
metastatic sites (such as liver and lung). 
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Figures 
 
 
 
 
 
Figure 2.1: Gas1, Boc, and Cdon are expressed in the normal and neoplastic 
pancreas 
(A) RT-qPCR analysis for Gas1, Boc, and Cdon in control (n=3), acute pancreatitis 
(n=4), and KC pancreata 3 wk following caerulein-induced pancreatitis (n=5). (B) 
Schematic of Gas1 and Boc reporter strains and KC model (left panels). Beta-
galactosidase (β-gal) and Alkaline Phosphatase (AP) staining for Gas1 and Boc 
reporter expression in normal and neoplastic pancreata (right panels). Scale bars, 
50μm.  
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Figure 2.2: GAS1, BOC, and CDON are expressed in the normal and 
neoplastic pancreas 
Antibody detection of GAS1, BOC, and CDON in (A) normal pancreas from 
wildtype mice, (B) PanIN-bearing pancreas from KC mice 3 weeks following 
caerulein-induced pancreatitis, or (C) tumor bearing mouse pancreata from 
KPC mice. Scale bars, 20μm.  
(Data/Image Credit: Dr. Yaqing Zhang) 
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Figure 2.3: Gas1 is co-expressed with SMA and Vimentin in the neoplastic pancreas 
Antibody detection of Gas1LacZ/+ β-gal (green) and (A) CD45/E-cadherin (red/magenta), (B) 
CD31 (magenta), (C) SMA (red), and (D) Vimentin (red) in KC and KC;Gas1LacZ/+ PanIN 
lesions. DAPI (blue) marks nuclei. White arrows indicate separate β-gal and CD45 
expression; yellow arrows indicate co-expression of β-gal with SMA and Vimentin. Scale 
bar, 20μm. 
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Figure 2.4: Gas1 is expressed by fibroblasts in the neoplastic pancreas 
Individual channel images of (A) DAPI (blue), -gal (green), CD45 (red), and E-
cadherin (magenta); (B) DAPI (blue), -gal (green), CD31 (magenta), and SMA 
(red); (C) DAPI (blue), -gal (green), and SMA (red); and (D) DAPI (blue), -gal 
(green), and Vimentin (red)  in KC;Gas1LacZ/+ PanIN lesions. Scale bar, 20μm 
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Figure 2.5: Boc is expressed by fibroblasts in the neoplastic pancreas 
Individual channel images of (A) DAPI (blue), AP (green) and SMA (red). (B) 
DAPI (blue), E-cadherin (green) and AP (red); and (C) DAPI (blue), CK19 
(green) and AP (red) in KC;BocPLAP/+ PanIN lesions. Scale bar, 20μm.  
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Figure 2.6:  Shh expression is restricted to the pancreatic tumor cells, whereas HH co-
receptor expression is restricted to fibroblasts 
(A) Shh expression in mouse pancreatic tumor cells, fibroblasts and flow cytometry-isolated 
CD11b+;F4/80+ macrophages. (B) Gas1 expression in mouse pancreatic tumor cells, 
fibroblasts, and flow cytometry-isolated CD11b+;F4/80+ macrophages. (C) RT-qPCR analysis of 
Gas1, Boc, and Cdon normalized to Vimentin expression in control and KC pancreas.  
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Figure 2.7: Gas1, Boc, and Cdon are expressed in human pancreatic 
cancer associated fibroblasts. 
A) GAS1, BOC and CDON expression in human pancreatic tumor tissue, 
and adjacent, non-tumor pancreas. (B) RT-qPCR analysis of GAS1, BOC 
and CDON expression in primary human tumor cells and cancer 
associated fibroblasts (CAFs). (C) VIMENTIN and E-CADHERIN 
expression in primary human tumor cells and human CAFs. 
cDNA from human tumor samples and human tumor cells and CAFs 
generously provided by Dr. Diane Simeone 
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Figure 2.8: Stromal deletion of Gas1 and Boc impairs HH-responsiveness, but 
promotes tumor growth. 
(A) RT-qPCR analysis of Gli1 and Ptch1 on SHH-stimulated MEFs. (B) Schematic 
of subcutaneous tumor injection experiment. (C) Quantitation of final tumor size in 
co-injection experiments of MEFs with Hs766T human tumor cell line. (D) Tumor 
growth curve for co-injection experiments of MEFs with MiaPaca human tumor cell 
line. 
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Figure 2.9: Stromal deletion of Gas1 and Boc impairs promotes the growth of large, 
vascularized tumors 
(A) Histopathological analysis of tumors following co-injection of Hs766T cells with MEFs. 
Scale bar, 50μm, inset scale bar 50μm. H&E staining (left panels) and Gomori trichrome 
(inset, left panels). Antibody detection of β-gal (green) and CD31 (red); right panels). DAPI 
(blue) marks nuclei. Scale bar 50μm, inset scale bar 50μm. (B) Quantitation of CD31 
staining. 
 
 
62 
 
 
 
 
Figure 2.10: Gas1-/-;Boc-/- pancreatic fibroblasts have impaired HH-
responsiveness, similarly to MEFs. 
(A) Schematic of pancreatic fibroblast isolation. RT-qPCR analysis of Gli1 and Ptch1 
on SHH-stimulated pancreatic fibroblasts. (B) Expression of SHH in human pancreatic 
tumor cells; moving from highest expression to lowest: Hs766T human pancreatic 
tumor cell line, 1319 human pancreatic tumor primary cells, UM2 human pancreatic 
tumor primary cells.  
1319 and UM2 primary human pancreatic cells generously provided by Dr. Diane 
Simeone 
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Figure 2.11: Gas1-/-;Boc-/- pancreatic fibroblasts promote the growth of 
large, vascularized tumors.   
(A) Quantitation of final tumor size in co-injection experiments with 1319 primary 
tumor cells human tumor cells with pancreatic fibroblasts. (B) Histopathological 
analysis of tumors following co-injections. H&E staining and Gomori trichrome 
(inset). Scale bar, 20μm, inset scale bar, 20μm. (C) Quantitation of CD31 staining. 
(D) Antibody detection of β-gal (green) and CD31 (red). DAPI (blue) marks nuclei. 
Scale bar, 20μm, inset scale bar 20μm.  
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Figure 2.12: Dosage-dependant HH signaling differentially promotes pancreatic 
tumor growth. 
(A) RT-qPCR analysis for Gli1 and Ptch1 on SHH-stimulated MEFs. (B) Schematic of 
subcutaneous tumor injection experiment. (C) Quantitation of final tumor size. (D) Growth 
curve for subcutaneous tumors.   
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Figure 2.13: Dosage-dependant HH signaling differentially promotes pancreatic 
tumor proliferation. 
(A) Histopathological analysis of tumors following co-injection of 1319 cells with MEFs. 
H&E staining and Gomori trichrome (inset). Scale bar, 20μm, inset scale bar 20μm.  
Antibody detection of (B) Cleaved Caspase 3 and (C) Ki67. Scale bar, 20μm.  
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Figure 2.14: Co-injected fibroblasts and HH ligand expression persist in 
subcutaneous tumors.  
(A) -gal reporter expression in subcutaneous tumor cohorts. Scale bar, 20μm. 
Quantitation of -gal staining. (B) RT-qPCR analysis of SHH in subcutaneous 
experiment cohorts with MEF lines 
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Figure 2.15: Dosage-dependent HH signaling does not affect ECM deposition. 
(A) Antibody detection of Vimentin (green) and Ck19 (red) Scale bar, 20μm. (B) 
Quantitation of Vimentin staining. (C) RT-qPCR analysis of Collagen I expression in 
subcutaneous experiments with pancreatic fibroblasts (left graph) and MEFs (right graph).  
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Figure 2.16: Dosage-dependant HH signaling differentially promotes 
pancreatic tumor vascularity. 
 (A) Antibody detection of -gal (green) and CD31 (red) in tumor tissue following 
co-injection of 1319 cells with MEFs. DAPI (blue) marks nuclei. Scale bar 50μm, 
inset scale bar 50μm. (B) Quantitation of CD31 staining.  
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Figure 2.17: Differential expression of angiogenic factors in fibroblasts. 
RT-qPCR analysis of Vegfa, Anpgt1, and Anpgt2 in (A) pancreatic fibroblasts and 
(B) in MEFs.  
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Figure 2.18: Angiogenesis regulation by fibroblasts in response to 
modulation of Hedgehog signaling. 
(A) RT-qPCR analysis of Vegfa, Angiopoietin 1 and Angiopoietin 2 in 
pancreatic fibroblasts. (B) Percent change in angiogenic gene expression in 
pancreatic fibroblasts in response to SHH treatment. (C) Chicken 
chorioallantoic membrane (CAM) assays with pancreatic fibroblasts and 
MEFs. Scale bar, 2mm.  
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Figure 2.19: Dosage-dependant HH signaling differentially promotes pancreatic 
tumor growth and vascularity in CAM assays. 
(A) Chicken CAM assay with 1319 cells and pancreatic fibroblasts. (B) Quantitation of 
CAM tumor area. (C) CAM assays with KPC mouse derived tumor cells (65671) and 
pancreatic fibroblasts. Scale, bar 2mm. (D) Chicken CAM assay with 1319 cells and 
MEFs. (E) Quantitation of CAM tumor area. Scale bar, 2mm.  
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Figure 2.20: Working model of dosage-dependent regulation of tumor 
growth and angiogenesis by Hedgehog signaling. 
Fibroblasts with all three co-receptors, and thus a normal HH response, respond 
to tumor-derived HH ligand by promoting tumor growth. In contrast, fibroblasts 
missing all three co-receptors, and thus a severely reduced ability to respond to 
HH, do not promote tumor growth. However, fibroblasts missing two co-
receptors, with a moderately reduced ability to respond to HH, promote the 
growth of large, vascular tumors compared to normal fibroblasts. Taken 
together, this points towards a dosage-dependant effect of HH signaling on 
tumor growth and angiogenesis. 
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CHAPTER THREE 
The Transcription Factor Gli1 Modulates the Inflammatory Response During 
Pancreatic Tissue Remodeling.1 
 
Abstract 
Pancreatic cancer, one of the deadliest human malignancies, is almost uniformly 
associated with a mutant, constitutively active form of the oncogene Kras.  Studies in 
genetically engineered mouse models have defined a requirement for oncogenic KRAS 
in both the formation of PanINs -the most common precursor lesions to pancreatic 
cancer- and in the maintenance and progression of these lesions. Previous work using 
an inducible model allowing tissue-specific and reversible expression of oncogenic Kras 
in the pancreas indicates that inactivation of this GTPase at the PanIN stage promotes 
pancreatic tissue repair. Here, we extend these findings to identify GLI1, a 
transcriptional effector of the Hedgehog pathway, as a central player in pancreatic 
tissue repair upon Kras inactivation. Deletion of a single allele of Gli1 results in improper 
stromal remodeling and perdurance of the inflammatory infiltrate characteristic of 
                                                          
1 Originally published as: Mathew, E., Collins, M., Fernandez-Barrena, M.G.,  Holtz, 
A.M., Yan, W., Hogan, J.O., Tata, Z., Allen, B.L., Fernandez-Zapico, M.E., and Pasca di 
Magliano, M. (2014) The Transcription Factor Gli1 Modulates the Inflammatory 
Response During Pancreatic Tissue Remodeling. Journal of Biol. Chem. 289(40): 
27727-27743. (doi:10.1074/jbc.M114.556563) 
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pancreatic tumorigenesis. Strikingly, this partial loss of Gli1 affects activated 
fibroblasts in the pancreas, and the recruitment of immune cells that are vital for tissue 
recovery. Analysis of the mechanism using expression and chromatin 
immunoprecipitation assays identified a subset of cytokines including IL-6, mIL-8, Mcp-1 
and M-csf (Csf1) as direct GLI1 target genes potentially mediating this phenomenon. 
Finally, we demonstrate that canonical Hedgehog signaling, a known regulator of Gli1 
activity, is required for pancreas recovery. Collectively, these data delineate a new 
pathway controlling tissue repair and highlight the importance of GLI1 in regulation of 
the pancreatic microenvironment during this cellular process. 
Introduction 
Pancreatic cancer is among the deadliest of human malignancies. The median 
survival is less than 6 months, and this prognosis has not changed in almost 50 years 
(1). Pancreatic cancer is preceded by precursor lesions, the most frequent being 
pancreatic intraepithelial neoplasias (PanINs) (2). Both PanINs and pancreatic cancer 
are almost uniformly associated with the presence of a mutant form of KRAS, most 
commonly KRASG12D (2-5). In mice, pancreatic cancer can be modeled by expressing 
oncogenic Kras in the pancreas epithelium (6,7). The induction of pancreatitis, a known 
risk factor for the development of pancreatic cancer (8), in mice expressing oncogenic 
Kras leads to rapid PanIN formation (9-11). In wildtype mice, the acute inflammatory 
response during pancreatitis is followed by rapid tissue repair over the course of several 
days (12). In contrast, mice bearing mutant Kras undergo rapid fibrosis and PanIN 
development upon induction of pancreatitis (11,13). Although the biology of these 
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phenomenona is clearly established, the molecular mechanism modulating tissue repair 
remains elusive.  
In the current study, we identified a novel mechanism underlying pancreas repair 
after pancreatitis and Kras-driven, inflammation-induced pancreatic carcinogenesis. We 
demonstrate that the transcription factor GLI1 is required for pancreatic tissue 
remodeling after damage. Our studies revealed that a reduction in the dosage of Gli1, 
through genetic inactivation of one Gli1 allele, caused impaired tissue repair following 
induction of pancreatitis, altering the remodeling of the stroma.  Furthermore, we 
identified a subset of known immune system regulators as GLI1 direct targets including 
IL-6, mIL-8, Mcp-1 and M-csf (Csf1). Finally, we detected a reduction in the infiltration of 
macrophages, thus possibly explaining the impaired tissue remodeling. Our results 
define a novel mechanism controlling pancreatic tissue repair and identified a dosage-
dependent role of the transcription factor GLI1 in the regulation of inflammatory 
responses in the pancreas.  
Materials and Methods 
Mice  
Mice were housed in specific pathogen-free facilities of the University of Michigan 
Comprehensive Cancer Center. This study was approved by the University of Michigan 
University Committee on Use and Care of Animals (UCUCA) guidelines. p48Cre 
(Ptf1aCre) mice (14) were intercrossed with TetO-KrasG12D (15) and Rosa26rtTa/rtTa (16) 
to generate p48Cre; TetO-KrasG12D; Rosa26rtTa/rtTa (iKras*) triple mutants (17). Gli1lacZ/lacZ 
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mice (18) (Jackson Laboratories stock #008211) were bred with iKras* animals to 
generate iKras*Gli1lacZ/+  mice. LSL-KrasG12D mice were bred with p48Cre and Gli1lacZ/lacZ 
mice to create KC double transgenics (7) and KC;Gli1lacZ/+ triple transgenics. 
Doxycycline (DOX) (Sigma) was administered in the drinking water at a concentration of 
0.2g/L in a solution of 5% sucrose and replaced every 3-4 days. Acute pancreatitis was 
induced by 2 series of 8 hourly intraperitoneal injections with caerulein (Sigma) at a 
concentration of 75μg/kg over a 48-hour period, as previously described (11).  
Immunohistochemistry and Immunofluorescence  
These assays were performed as previously described (17). Primary antibodies used 
were β-Gal/lacZ (1:200, Abcam), CD45 (1:200, BDPharm), CK19 (1:100, Iowa 
Developmental Hybridoma Bank), F4/80 (1:100, BMA Biomedicals), phospho-ERK1/2 
(1:100, Cell Signaling), Ki67 (1:100, Vector Laboratories), SMA (1:1000, Sigma), and 
Vimentin (1:100, Cell Signaling). Images were taken with an Olympus BX-51 
microscope, Olympus DP71 digital camera, and CellSens standard v1.6 software. For 
immunofluorescence, Alexa Fluor (Invitrogen) secondary antibodies were used. Cell 
nuclei were counterstained with DAPI (Invitrogen). The images were acquired using an 
Olympus IX-71 confocal microscope and FluoView FV500/IX software or a Leica 
Inverted SP5X confocal microscope with Leica Applications Suite Advanced 
Fluorescence (LAS AF) software.  
Histopathology  
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Briefly, de-identified slides were examined by an expert pathologist (W.Y.).  For each 
slide, 5 low magnification pictures were taken from the center, top right, top left, bottom 
right and bottom left locations in order to cover most of the area of each section. A 
minimum of 50 total acinar or ductal clusters was counted from at least 3 independent 
animals for each group, as previously described (19). Each cluster counted was 
classified as Acinar, Acinar-Ductal Metaplasia (ADM), PanIN1A, 1B, 2 or 3 based on the 
classification consensus (20). The data was expressed as percentage of total counted 
clusters. Error bars represent SEM.  
Quantification of Trichrome Staining  
Images of iKras* and iKras*Gli1lacZ/+ Gomori Trichrome-stained sections were taken with 
a Leica MZFLIII dissection microscope and Olympus DP72 camera. Trichrome positive 
areas were determined with Image Pro Plus v4 software (MediaCybernetics). The data 
was expressed as a percent of trichrome positive area and averaged per timepoint. 
Error bars represent SEM.  
Reverse Transcription Quantitative PCR (qRT-PCR)  
 Tissue for RNA extraction was prepared through overnight incubation in RNAlater-ICE 
(Ambion) at -20oC, then isolated using RNeasy Protect (Qiagen) according to the 
manufacturer’s instructions. Reverse transcription reactions were conducted using a 
High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems). Samples for qRT-
PCR were prepared with 1x SYBR Green PCR Master Mix (Applied Biosystems) and 
various primers listed in Table 3.1.  All primers were optimized for amplification under 
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reaction conditions as follows: 95°C 10 minutes, followed by 40 cycles of 95°C 15 
seconds and 60°C 1 minute. Melt curve analysis was performed for all samples after 
completion of the amplification protocol. Cyclophilin was used as the housekeeping 
gene expression control. 
Cell Culture  
Mouse-derived tumor cell lines were cultured for 3 days after which conditioned media 
was collected, centrifuged and filtered. For cell stimulation, conditioned media was 
mixed with low-serum media (0.5%) at a 1:1 ratio.  Mouse pancreatic fibroblast lines 
were derived from WT and Gli1lacZ/+ pancreata. Briefly, freshly isolated pancreas were 
minced with sterile scissors then digested in 1mg/mL collagenase. Digested samples 
were then filtered through a 100µm strainer and cultured in IMDM supplemented with 
10% FBS and 1% penicillin/streptomycin (Gibco). Cells were serum-starved (IMDM 
supplemented with 0.5% serum) for 36 hours prior to addition of conditioned media, and 
samples collected 0 hours, 6 hours, and 24 hours following stimulation.  Mouse NIH/3T3 
cells (ATCC, VA) were plated at 200,000 cells/well in 6-well plates in DMEM + 10% FBS 
+ penicillin/streptomycin. After 24 hours cells were switched to low serum media (DMEM 
+ 0.5% FBS) and treated with 100µl of conditioned media from control vector - 
(pcDNA3) or Sonic Hedgehog N-Terminus (NShh-pcDNA3) transfected COS7 cells. 
RNA was extracted after 24 hours of treatment and subjected to qRT-PCR as described 
above. The mouse embryonic fibroblast line was a gift from Dr. Shilatifard (Stowers 
Institute for Medical Research, Kansas City, MO) (21) and it was cultured in DMEM 
(Invitrogen) supplemented with 10% FBS (SAFC BioScience). 
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Flow Cytometry  
Single cell suspensions from the pancreas and spleen were prepared as follows: freshly 
isolated organs were minced with sterile scalpels prior to incubation in 1mg/mL 
collagenase (Sigma-Aldrich) in HBSS for 15min at 37°C. Cell suspensions were then 
passed through a 40µM strainer. Single cell suspensions were prepared in HBSS/2% 
FBS. Antibodies used were CD45-Pacific Orange (1:50, Invitrogen), Gr1-FITC (1:50, BD 
Pharm), F4/80-PE-CY5 (1:50, eBioscience), CD11b-APC-CY7 (1:50, BD Pharm), CD3-
PE (1:50, BD Pharm), CD8-APC-CY7 (1:50, BD Pharm), CD4-Pacific Blue (1:50, BD 
Pharm), CD25-APC (1:50, BD Pharm), Foxp3-FITC (1:50, eBioscience). Flow cytometry 
analysis was performed on a CyanTM ADP Analyzer (Beckman Coulter) and data 
analyzed using Summit 4.3 Software.  
Chromatin Immunoprecipitation Assay (ChIP)  
ChiP was conducted following the Magna ChIP kit protocol (Upstate). Briefly, 4 × 106 
cells, cultured in DMEM (Invitrogen) supplemented with 10% FBS (SAFC BioScience), 
were cross-linked with 1% formaldehyde directly into the media for 10 min at room 
temperature. The cells were then washed and scraped with phosphate-buffered saline 
and collected by centrifugation at 800 × g for 5 min at 4°C, resuspended in cell lysis 
buffer and incubated on ice for 15 min. The pellet was then resuspended in nuclear lysis 
buffer and sheared to fragment DNA to ~700 bp. Samples were then 
immunoprecipitated using a GLI1 antibody (Novus Biologicals), normal rabbit IgG 
(Upstate) overnight at 4 °C on a rotating wheel. Following immunoprecipitation, samples 
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were washed and eluted using the chromatin immunoprecipitation kit in accordance with 
the manufacturer's instructions. Cross-links were removed at 62°C for 2 h, followed by 
10 min at 95°C, and immunoprecipitated DNA was purified (Upstate) and subsequently 
amplified by real-time PCR. PCR was performed using primer sets for areas containing 
potential Gli1 binding sites in the M-cp1, M-csf, IL-6 and IL-8 promoter sequence: M-
cp1, 5´-caaatctcaggtccagggaag-3´ (forward) and 5´-gccaggcatagtcagttgt-3´(reverse); M-
csf, 5´-gcaggatatctgacttgtgacc-3´(forward) and 5´-caacccattcctcccagttaag-3´(reverse); 
IL-6, 5´-gcagtgggatcagcactaacagat-3´ (forward) and 5´-cctggacaacagacagtaatgttg-
3´(reverse); IL-8, 5´-caacagaactggtgcatctataag-3´ (forward) and 5´-
gccaactgctctaggacat-3´(reverse); Gli1-negative region in Chromosome 11 5’-
tcccaggagtggctagaa-3’ (forward) and 5’-gctctgaggcagccttt-3’ (reverse). Quantitative 
SYBR PCR was performed in triplicate for each sample or control using the C1000 
Thermal Cycler (Bio-Rad). 
Statistical Analysis 
The data are expressed as the mean± standard deviation. One-way ANOVA with a 
Tukey post-test was used to compare data between groups. A P value <0.05 was 
considered statistically significant. 
Results 
Gli1 is Required for Pancreas Recovery Following Pancreatitis or Inactivation of 
Oncogenic Kras  
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 To investigate the role of GLI1 in tissue repair following acute pancreatitis as 
well as during early stages of pancreatic carcinogenesis, we used a mouse model 
where one Gli1 allele was replaced with a lacZ cassette, generating a Gli1 hemizygous 
animal (18). We initially induced pancreatitis in wildtype (WT) and Gli1lacZ/+ mice with the 
cholecystokinin agonist caerulein (22). Both WT and Gli1 lacZ/+ mice exhibited the 
characteristic acinar damage and influx of immune cells and activated fibroblasts 2 days 
after pancreatitis induction (Figures 3.1A and 3.1B). However, while normal tissue 
architecture and function was restored in WT pancreata after one week (Figure 3.1A), 6 
out of 10 Gli1 lacZ/+ mice failed to resolve the fibroinflammatory response (Figure 3.1B, 
black arrows). Interestingly, the failure to resolve pancreatitis did not increase in 
Gli1lacZ/lacZ mice (Figure 3.2).  
To determine whether Gli1 was similarly required to mediate pancreas repair 
following oncogenic KrasG12D inactivation, we crossed Gli1lacZ/lacZ mice with the iKras* 
mouse model of pancreatic cancer -that allows for tissue-specific and reversible control 
of oncogenic KrasG12D- to generate iKras*Gli1lacZ/+ animals. In iKras* mice, activation and 
inactivation of the oncogene is obtained by the addition or removal of doxycycline 
(DOX) from the drinking water (Figure 3.3A). The iKras* mouse develops PanINs and a 
pronounced desmoplastic stroma upon oncogenic Kras activation followed by the 
induction of acute pancreatitis (17). Conversely, inactivation of oncogenic Kras 
expression in low-grade PanINs leads to complete tissue recovery. We administered 
DOX to 4 to 6 week old iKras* and iKras*Gli1lacZ/+ mice to express KrasG12D and then 
induced pancreatitis. We harvested pancreata 3 weeks later  (n=3-5) (Figure 3.3B). 
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Both iKras* and iKras*Gli1lacZ/+ mice exhibited a substantial acinar cell loss and PanIN 
formation with accumulation of desmoplastic stroma (Figures 3.4A, 3.4B, and 3.5). 
Thus, inactivation of one allele of Gli1 did not affect pancreatitis-driven PanIN formation 
in this model.  
We then inactivated KrasG12D expression, by removing DOX from the water, and 
harvested tissue after 3 days, 2 weeks, and 5 weeks (n=3-5). Notably, upon KrasG12D 
inactivation, recovery of the acinar cell compartment was apparent after only 3 days in 
iKras* mice, whereas iKras*Gli1lacZ/+ mice displayed delayed recovery of the acinar 
compartment (Figures 3.4A, 3.4B, and 3.5). Two weeks following KrasG12D inactivation, 
recovery of the acinar compartment as well as comprehensive remodeling of the stroma 
was complete in iKras* mice. In contrast, iKras*Gli1lacZ/+ mice retained low-grade PanIN 
lesions and displayed a prominent amount of stroma even at the 5 week time point 
(Figure 3.4B and 3.5). Using β-Gal staining to follow Gli1 expression, we found that 
Gli1 levels increased throughout the stroma after 3 weeks of oncogenic Kras activation, 
and persisted even after Kras inactivation (Figure 3.4B). These data suggest a critical 
role for Gli1 dosage during tissues recovery following both caerulein-induced 
pancreatitis and after inactivation of oncogenic Kras. 
Loss of Gli1 Impairs Stromal Remodeling During Tissue Repair   
To determine which cell types in the pancreas express Gli1, we performed co-
immunofluorescence for β-Gal along with various epithelial, fibroblast, and immune cell 
markers in iKras*Gli1lacZ/+ mice. First, we observed a distinct separation of β-Gal+ cells 
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and CK19, a marker for pancreatic ducts and PanINs, indicating that ducts and 
neoplastic epithelial cells did not express Gli1 (Figure 3.6A).  In contrast, we identified 
widespread co-expression of β-Gal with SMA, a marker of activated fibroblasts, as well 
as co-localization with Vimentin, another fibroblast marker (Figure 3.6B, and data not 
shown). We additionally observed co-expression of Gli1 with a subset of the 
macrophages within the tissue, identified by the marker F4/80 (Figure 3.6C).  
In order to determine whether the expression pattern of Gli1 was conserved in a 
different model of KrasG12D-driven pancreatic carcinogenesis, we crossed Gli1lacZ/+ 
reported mice with the KC mouse model of pancreatic cancer (Pft1a-Cre;LSL-KrasG12D) 
(7).  We collected pancreata from KC;Gli1lacZ/+ mice 3 weeks following the induction of 
pancreatitis, when widespread PanINs are expected. Similar to our findings in the 
iKras*Gli1lacZ/+ mice, β-Gal expression in KC;Gli1lacZ/+ mice was detected in activated 
fibroblasts and in a subset of immune cells (expressing CD45) but not in epithelial cells 
(Figures 3.7A-D). Thus, stromal expression of Gli1 is common to caerulein-induced 
pancreatitis and 2 independent models of pancreatic cancer. 
Next, we wanted to assess the stroma that failed to remodel in iKras*Gli1lacZ/+ 
mice.  Thus, we performed a Gomori Trichrome stain to visualize and quantify collagen 
deposition. Three weeks after KrasG12D activation, both iKras* and iKras*Gli1lacZ/+ mice 
pancreata had an abundance of collagen deposition, which is a hallmark of the 
desmoplastic response in the neoplastic pancreas (23). The collagen deposition 
persisted at the 3 day timepoint, but fully resolved by 2 weeks following KrasG12D 
inactivation in iKras* mice. In contrast, in iKras*Gli1lacZ/+ mice, abundant collagen 
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deposition was still observed throughout the stroma at 2 weeks, indicating a delay or 
impairment of the remodeling process (Figures 3.8A and 3.8B).  
Both in iKras* and iKras*Gli1lacZ/+ pancreatic tissues active proliferation 
(measured by Ki67 immunostaining) was observed in both the epithelial and stromal 
compartments 3 weeks following KrasG12D activation (Figure 3.9A). Subsequent 
inactivation of oncogenic Kras shifted the majority of cell proliferation to the epithelial 
compartment in both genotypes (Figure 3.9A). Additionally, in the presence of 
oncogenic Kras, phospho-ERK1/2 (pERK1/2) - a downstream effector of Kras - was 
elevated in the epithelial compartment (Figure 3.9B). Upon KrasG12D inactivation, 
pERK1/2 levels decreased in the epithelium and there was a transient increase in the 
stroma of iKras* pancreata, as previously described (17). Interestingly, in iKras*Gli1lacZ/+ 
mice, elevated pERK1/2 levels in the stroma persisted even at 5 weeks following 
KrasG12D inactivation (Figure 3.9B).  
Finally, we assessed SMA expression to mark the reactive stromal compartment. 
Three weeks following induction of KrasG12D expression, robust SMA expression was 
detected in the stroma of both sets of mice (Figure 3.10A, black arrows). This 
expression rapidly decreased in iKras* animals upon KrasG12D inactivation. However, in 
iKras*Gli1lacZ/+ mice, SMA expression persisted longer than in iKras* mice. By 2 weeks, 
however, most of the fibroblasts persisting in the pancreas did not express SMA (Figure 
3.10A, white arrows), thus indicating that reduced Gli1 dosage impaired remodeling 
but did not cause sustained fibroblast activation.  
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Gli1 Regulates a Distinct Profile of Immune System Regulators  
Knowing the function of Gli1 as an effector of the Hedgehog (HH) pathway, we 
assessed the expression of HH pathway components in both iKras* and iKras*Gli1lacZ/+ 
mice. In the normal adult mouse pancreas, HH pathway components are not expressed 
at detectable levels. However, expression of HH pathway components increases in 
PanINs (24). In iKras*Gli1 lacZ/+ mice, the expression of HH pathway components was 
reduced compared to iKras* mice, indicating that one allele of Gli1 was not sufficient to 
maintain the level of pathway activation found in PanINs. (Figures 3.11A-F). Upon 
KrasG12D inactivation, expression of these HH pathway genes decreased over time. 
Intriguingly, we observed a spike of Gli1 expression in iKras* mice after 2 weeks of 
KrasG12D inactivation (Figure 3.11A), consistent with a role for this gene in pancreatic 
recovery and remodeling.  
To investigate potential mechanisms by which Gli1 regulates pancreatic 
recovery, we assessed the expression of cytokines involved in tissue remodeling. First, 
we performed qRT-PCR analysis to assess differences in cytokine production between 
iKras* and iKras*Gli1lacZ/+ pancreatic tissue (scheme in Figure 3.12A). We detected a 
significant decrease in IL-6 expression in iKras*Gli1lacZ/+ pancreas (Figure 3.12B). 
Likewise, we detected a significant reduction in both Mcp-1 and the murine homolog of 
IL8 (mIL-8) in iKras*Gli1lacZ/+ pancreata (Figures 3.12C and 3.12D). These cytokines all 
regulate leukocyte accumulation and function (25); however, only IL-6 was previously 
described as a GLI1 target (26). Additionally, transcription of M-csf, a critical factor for 
macrophage differentiation and function (27), was reduced in iKras*Gli1lacZ/+ pancreas 
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(Figure 3.12E). These data suggest that GLI1 may regulate pancreas recovery through 
the expression of secreted factors involved in immune system function.  
To test whether Gli1 loss affected cytokine production specifically in fibroblasts, 
we extracted pancreatic fibroblasts from untreated WT and Gli1lacZ/+ mice (scheme in 
Figure 3.13A), followed by serum-starvation and treatment with either cancer cell 
conditioned media (CCM) from primary iKras* tumor cells (28) or control (Ctrl) media for 
0, 6, and 24 hours; we then collected cells for RNA extraction (scheme in Figure 
3.13A). In parallel, fibroblasts were treated with conditioned medium from control or 
SHH-expressing COS7 cells. As expected, Gli1 and Ptch1 expression increased in WT 
fibroblasts treated with SHH-expressing COS7 cell conditioned medium, as measured 
by qRT-PCR. Of note, Gli1 had a higher basal expression level but reduced Shh-
dependent activation in Gli1lacZ/+ fibroblasts. Moreover, the extent of Ptch1 activation 
was reduced in Gli1lacZ/+ fibroblasts. (Figure 3.13B). Over the course of experimental 
repeats, we found that Gli1 expression in WT fibroblasts was inconsistently increased 
after 6 hours, but always significantly increased by 24 hours. Further, transcription of IL-
6 was significantly increased 6 hours after exposure to CCM, in both WT and Gli1lacZ/+ 
cells. At 24 hours however, WT fibroblasts sustained significantly greater levels of IL-6 
transcription than Gli1lacZ/+ cells (Figure 3.13C). Expression of both Mcp-1 and mIL-8 
were also significantly reduced in Gli1lacZ/+ fibroblasts at both 6 hours and 24 hours post-
treatment (Figures 3.13D and 3.13E). Moreover, transcription of M-csf was also 
significantly reduced at 6 hours in Gli1lacZ/+ fibroblasts compared to their WT 
counterparts; however, by 24 hours levels of M-csf transcription were the same (Figure 
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3.13F).  Of note, as both WT and Gli1lacZ/+ fibroblasts express a basal level of GLI 
proteins, activation of target genes could occur even before new Gli1 is transcribed. 
These results identify multiple potential GLI1-dependent cytokine targets in pancreatic 
fibroblasts. 
To test whether these putative GLI1 targets were common to other fibroblast 
populations, we treated serum-starved NIH/3T3 cells with control-conditioned media 
(COS7-CM) or NSHH-conditioned medium (COS7-SHH) for 24 hours followed by 
assessment of cytokine expression by qRT-PCR (scheme in Figure 3.14A). We also 
included untreated cells to exclude any effects of the control-conditioned media. Gli1 
and Ptch1 were up-regulated in response to NSHH treatment, confirming increased HH 
pathway activity in these cells (Figure 3.14B). While we did not observe significant 
changes in the expression of Mcp-1 or M-csf, both IL-6 and mIL-8 were up-regulated in 
response to NSHH treatment (Figure 3.14B). Therefore, IL-6 and mIL-8 may be general 
HH targets in fibroblasts, while Mcp-1 and M-csf might be pancreas-specific. 
Finally, we determined whether these cytokines were direct GLI1 target genes. 
Bioinformatic analysis identified putative GLI1 binding sites in the promoters of these 
cytokines (Figure 3.15A). To assess GLI1 binding to these sites we performed ChIP 
assays in mouse embryonic fibroblasts (MEFs). Endogenous GLI1 bound to the 
promoter of IL-6, mIL-8, Mcp-1 and M-csf (Figures 3.15B-E). We also observed GLI1 
binding on the Cyclin D1 promoter (Figure 3.15F), used as a positive control (29,30). To 
control for the specificity of GLI1 binding, we performed PCR in a region lacking 
canonical GLI1-binding sites. Importantly, GLI1 binding was not detected in this region 
92 
 
(Figure 3.15G). Taken together, these data indicate that several cytokines important in 
immune cell recruitment and function are direct GLI1 transcriptional targets whose 
expression is reduced upon loss of a single Gli1 allele. 
Immune Cell Infiltration is Regulated in a Gli1-dependent Manner  
To define if the altered cytokine expression profiles detected in Gli1lacZ/+ animals 
affected immune cell recruitment in vivo, we performed flow cytometry analysis on 
iKras* and iKras*Gli1lacZ/+ mice 3 weeks after pancreatitis. We quantified both the 
myeloid and T lymphocyte subsets recruited to the neoplastic pancreas. Since B 
lymphocytes are not reported to function in the wound healing process, we did not 
quantify their numbers in this analysis (31).   
We detected no difference in the overall population of CD45+ hematopoietic cells 
between iKras* and iKras*Gli1lacZ/+ mice (Figure 3.16A). Previous work characterizing 
the immune infiltrate of pancreatic cancer revealed a prominent leukocyte population, 
predominantly F4/80+/CD11b+ macrophages, that developed during PanIN formation 
and persisted through tumor development (32). Comparison of iKras* and 
iKras*Gli1lacZ/+ pancreata 3 weeks after KrasG12D activation revealed lower F4/80 
staining in the stroma of mice with reduced Gli1 dosage (Figure 3.16B). Flow cytometry 
analysis corroborated the decrease in CD11b+;F4/80+ macrophages (Figure 3.16C). 
Additional characterization of the myeloid populations revealed that immature myeloid 
cells (iMCs; Cd11b+;Gr-1+), a heterogeneous population of immature monocytes and 
granulocytes, was decreased in iKras*Gli1lacZ/+ samples compared to iKras* tissues 
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(Figure 3.16D). Both polymophonuclear-derived iMCs (PMN-iMCs) and mononuclear-
derived iMCs (Mo-iMCs) were reduced in iKras*Gli1lacZ/+ pancreata (Figures 3.16E and 
3.16F).   
Analysis of T cell subsets revealed significantly elevated CD3+ lymphocyte 
populations in the iKras*Gli1lacZ/+ pancreas (Figure 3.17A). More specifically, both 
CD3+/CD4+ Helper T helper cells (Figure 3.17B) and CD3+/CD8+ Cytotoxic T cells 
(Figure 3.17C) were significantly increased in iKras*Gli1 lacZ/+ pancreas. However, levels 
of CD3+/CD4+/CD25+/FoxP3+ Regulatory T cells were equivalent between iKras* and 
iKras*Gli1 lacZ/+ pancreas (Figure 3.17D). Thus, the changes in the myeloid cell subset 
correlated with the changes observed in the T cell populations. Moreover, upon 
matching qRT-PCR Gli1 expression with flow analyzed immature myeloid cell 
populations for individual iKras*Gli1 lacZ/+ mice, we found a positive correlation between 
Gli1 levels and myeloid cell infiltration (Figure 3.17E). Taken together, these data 
indicate a novel role for Gli1 in regulating the immune cell response in the neoplastic 
pancreas.  
Reduced Gli1 Expression Decreases M2 Macrophage Recruitment to the Pancreas  
During tissue recovery, macrophages play an important role in multiple aspects 
of the wound healing process (for review, see (33)).  In particular, alternatively activated 
macrophages (M2) can digest cell debris and extracellular matrix (ECM) components to 
promote tissue remodeling (34,35). Given the importance of M2 macrophages in tissue 
recovery, we tested whether a reduction in Gli1 affected their recruitment.  We 
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performed flow cytometry on pancreas after 3 weeks of KrasG12D activation, as well as 3 
days following subsequent KrasG12D inactivation to detect numbers of M2 
(CD11b+;CD64+;F4/80+;CD11c-;CD206+) and M1 (CD11b+;CD64+;F4/80+;CD206-
;CD11c+) macrophages. In both iKras* and iKras*Gli1 lacZ/+ mice, M2 macrophage 
numbers were comparably low at 3 weeks of KrasG12D activation. Interestingly, M2 
macrophage numbers increased significantly upon KrasG12D inactivation in iKras* mice. 
However, we detected a significant decrease in M2 macrophages in iKras*Gli1 lacZ/+ mice 
at this timepoint (Figure 3.17F). This population reduction was specific to M2 
macrophages, as M1 macrophage populations were comparable between iKras* and 
iKras*Gli1 lacZ/+ mice at both timepoints tested (Figure 3.17G).  Thus, the specific 
macrophage population that is critical for tissue repair is decreased in iKras*Gli1lacZ/+ 
mice. 
Canonical Hedgehog Signaling is Required for Pancreas Recovery  
To determine whether the loss of Gli1 affected pancreas tissue repair through the 
HH pathway (36), we used 2 complementary in vivo approaches. First, we investigated 
the ability of mice lacking expression of SHH ligand in the pancreatic epithelium (Pft1a-
Cre;Shhf/f) to recover from pancreatitis. Similar to Gli1LacZ/+ mice, Pft1a-Cre;Shhf/f mice 
displayed defects in stromal remodeling 1 week after pancreatitis (Figure 3.18). 
Second, we used a pharmacological method to inhibit canonical HH signaling. PanIN-
bearing iKras* mice were treated with either the Smo-antagonist LDE225 or with vehicle 
by oral gavage every 24 hours for 2 weeks following KrasG12D inactivation (Figure 
3.19A). As expected, vehicle-treated iKras* mice showed complete recovery of the 
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epithelium and remodeling of the stroma. In contrast, the vast majority of LDE225-
treated tissues did not recover (Figures 3.19B and 3.19C).  Similar to iKras*Gli1lacZ/+ 
mice, LDE225-treated iKras* pancreata showed improper stromal remodeling, with 
abundant residual collagen deposition (Figure 3.19C, bottom row).  LDE225-treated 
mice also displayed SMA and pERK1/2 positivity throughout the stroma, indicating a 
reactive stroma that failed to resolve (Figure 3.19C). Thus, canonical HH signaling is 
necessary for PanIN regression and stromal remodeling in the pancreas.   
To determine whether the cytokines we identified as GLI1 targets were regulated 
by canonical HH signaling, we treated WT pancreatic fibroblasts with CCM alone or with 
CCM and the selective Smoothened inhibitors SANT-1 or SANT-2 (scheme in Figure 
3.20A) (37).  After 6 hours of treatment, cells were collected for qRT-PCR analysis. 
CCM treatment induced expression of IL-6, Mcp-1, mIL-8, and M-csf, as seen 
previously. However, concomitant HH inhibition significantly reduced the level of 
induction, indicating that ligand-dependent HH signaling mediates activation of these 
targets (Figure 3.20B).  Collectively, our in vivo and in vitro data reveals a requirement 
for canonical HH signaling for cytokine expression in fibroblasts and for pancreas tissue 
repair.  
Discussion 
The HH signaling pathway is essential for proper embryonic development and 
adult tissue homeostasis (38). HH signaling culminates in the modulation of the GLI1 
family of transcription factors that in turn regulate the gene expression mediating HH-
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dependant cellular responses (for review see (39)). Mammals possess 3 GLI 
transcription factors, GLI1, GLI2 and GLI3. While both Gli2 and Gli3 mutant mice die 
embryonically or perinatally due to a range of HH-dependent developmental defects, 
Gli1 mutant mice are viable and fertile, and reach adulthood with no apparent 
impairment (40). However, recent studies indicate that these mice have defects in 
regulating inflammation and tissue repair following injury (41). Specifically, mice 
hemizygous for Gli1 are more susceptible to intestinal inflammation and chemical-
induced injury (42). Gli1+/- mice are also less susceptible to inflammation-induced 
metaplasia upon H. pylori infection (43). In humans, a variant of Gli1 with reduced 
transcriptional function confers higher susceptibility to irritable bowel disease mediated 
by an altered myeloid response (42). Thus, both in previous studies and in our work, 
Gli1 dosage appears to mediate critical aspects of myeloid cell function in the 
gastrointestinal system. These findings in could be explained with a threshold model, 
wherein the overall ratio of GLI activator and repressor are crucial for transcriptional 
output. Future studies will be required to examine the requirement for other GLI factors 
in pancreatic cancer. We have previously shown that GLI activity in pancreatic 
fibroblasts leads to expression of IL-6, an inflammatory cytokine that activates Stat3 in 
the pancreatic cancer cells (26). However, the regulation of Gli1 expression and its role 
in pancreatitis and tissue repair, and during the onset of pancreatic cancer has not been 
comprehensively addressed.  
Here, we investigated the role of Gli1 during tissue repair in the pancreas.  Unlike 
the stomach and intestine, which have a basal level of active HH signaling, components 
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of the HH pathway are undetectable in the normal pancreas both during development 
and in the adult tissue (24,44).  However, HH signaling is activated during pancreatitis 
(45), as well as in pancreatic cancer (46,47). The specific role of Gli1 during those 
processes, however, was not previously explored.  We investigated the effect of 
reducing Gli1 dosage in 2 pathologic contexts: induction of acute pancreatitis and 
pancreatitis-induced pancreatic carcinogenesis. Inactivation of a single copy of Gli1 
disrupted tissue repair following both pancreatitis and oncogenic Kras inactivation.  
We determined that Gli1 was primarily expressed in pancreatic fibroblasts. The 
primary function of fibroblasts is to secrete extracellular matrix proteins and thus provide 
structural integrity to connective tissues (48). However, these cells not only contribute to 
tissue homeostasis but also respond to epithelial damage. In addition to promoting 
epithelial recovery, fibroblasts secrete a range of immunomodulatory proteins, such as 
IL-6, MCP-1, and IL-8, which regulate immune cell function during both tissue damage 
and recovery (49,50). This function is critical, as improper immune cell recruitment has 
adverse effects on various aspects of tissue healing. Though fibroblast-mediated 
regulation of immune response is important for wound recovery, few studies have 
focused on the ability of these stromal cells to coordinate immune cell recruitment and 
function during neoplasia (51).  In this study we found that Gli1lacZ/+ fibroblasts had a 
significantly altered transcriptional profile compared to their WT counterparts in 
response to cancer cell conditioned media.  Notably, loss of Gli1 resulted in lower 
transcriptional levels of multiple potent factors that regulate immune cell migration and 
function, such as M-csf, Mcp-1, and mIL-8.  Consequently, we found that in vivo, the 
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profile of immune cells in the PanIN bearing pancreas is significantly altered; loss of 
Gli1 results in fewer myeloid cells and greater numbers of T cells.   
The precise regulation of the immune response is critical for tissue recovery. In 
particular, the monocyte-macrophage population plays a vital role; these cells 
participate in wound debridement, the removal of extracellular matrix and dead or 
damaged cells (31). In the liver, macrophage depletion during recovery from 
inflammatory injury resulted in impaired stromal remodelling. However, depletion of 
macrophages during injury induction led to an overall reduction in scar matrix (52). 
Likewise, our data suggests that the improper recruitment of myeloid cells, particularly 
M2 macrophages, leads to improper pancreatic repair in iKras*Gli1lacZ/+ mice.     
In summary, our studies show that Gli1 is a key modulator of pancreatic inflammation, 
through transcriptional regulation of cytokine production in pancreatic fibroblasts. A 
working model summarizing our findings is provided in Figure 3.21. 
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Figures 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1: Reduced expression of Gli1 delays tissue repair following 
pancreatitis 
(A) H&E (scale bars 50µm) and ß-Gal staining (scale bars 20µm) for (A) WT and 
(B) Gli1lacZ/+ mice either untreated or 2d and 1w following pancreatitis. Gli1lacZ/+ 
pancreata exhibit a delay in tissue recovery compared to WT, with some fibrotic 
areas remaining (black arrows) 1w post-pancreatitis.  
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Figure 3.2: Deletion of Gli1 delays tissue repair following pancreatitis 
(A) H&E (scale bars 50µm) and ß-Gal staining (scale bars 20µm) for  Gli1lacZ/lacZ  
mice either untreated or 2d and 1w following pancreatitis. Gli1lacZ/lacZ pancreata, 
like Gli1lacZ/+ pancreata, exhibit a delay in tissue recovery compared to WT, with 
some fibrotic areas remaining (black arrows) 1w post-pancreatitis.  
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Figure 3.3: Reduced expression of Gli1 impairs tissue recovery following 
oncogenic Kras inactivation. 
(A) Genetic makeup of iKras*Gli1lacZ/+  mice. (B) Experimental Design. Kras*=KrasG12D. 
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Figure 3.4: Reduced expression of Gli1 impairs tissue recovery following 
oncogenic Kras inactivation. 
(A) H&E (scale bars 50µm) for iKras* and (B) H&E (scale bars 50µm) and ß-Gal 
staining (scale bars 20µm) iKras*Gli1lacZ/+ pancreata with Kras* active (Kras* ON) 
for 3w, and following Kras* inactivation (Kras* OFF) 3d, 2w, and 5w.  
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Figure 3.5: Histopathological analysis of impaired tissue recovery following 
oncogenic Kras inactivation. 
Histopathological analysis of iKras* and iKras*Gli1lacZ/+ tissues at the indicated time points, 
data represent mean ± SEM.   
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Figure 3.6: Identification of Gli1 expressing cells in the stroma 
Co-immunofluorescence for ß-Gal (green) and (A) CK19, (B) SMA, and 
(C) F4/80 (red) in iKras* and iKras*Gli1lacZ/+ PanIN lesions. Nuclei 
denoted by DAPI (blue). Scale bars 20µm. 
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Figure 3.7: Identification of LacZ positive cells in KC mice 
Coimmunofluorescence for ß-Gal (green) and (A) CK19, (B) SMA, 
(C) Vimentin, and (D) CD45 in KC and KC; Gli1LacZ/+ mice 3 weeks 
post-pancreatitis. Nuclei denoted by DAPI (blue). Scale bars 20µm. 
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Figure 3.8: Gli1 is required for stroma remodeling.  
(A) Gomori Trichrome staining of iKras* and iKras*Gli1lacZ/+ 
pancreata. Scale bar 50um. (B) Quantification of Trichrome 
positive area (expressed as percentage of total area). Data 
represent mean ± SEM.  
. 
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Figure 3.9: Gli1 is required for stroma remodeling.  
Immunohistochemistry for (A) Ki67 and (B) pERK1/2 in iKras* and 
iKras*Gli1lacZ/+ pancreata. Scale bars 20µm. 
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Figure 3.10: Characterization of iKras* and iKras*Gli1lacZ/+ tissues upon 
Kras* inactivation. 
(A) Immunohistochemistry for SMA in iKras* and iKras*Gli1lacZ/+ pancreata. Black 
arrows indicate fibroblasts positive for SMA expression, white arrows indicate 
fibroblasts negative for SMA expression. Scale bars 20µm.  
 
110 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.11: Characterization of HH signaling in iKras* and iKras*Gli1lacZ/+ 
tissues upon Kras* inactivation. 
qRT-PCR for HH signaling pathway components (A) Gli1, (B) Ptch1, (C) 
Hhip1, (D) Gli2, and (E) Shh. 
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Figure 3.12: Reduced expression of Gli1 alters HH response and the 
cytokine transcriptional profile of pancreatic tissue. 
(A) Experimental design. qRT-PCR analysis for (B) IL-6 (C) Mcp-1 (D) mIL-8 and 
(E) M-csf in iKras* and iKras*Gli1lacZ/+ pancreata.  
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Figure 3.13: Reduced expression of Gli1 alters Hh response and the 
cytokine transcriptional profile of pancreatic fibroblasts. 
(A) Experimental design. qRT-PCR analysis for (B) Hh target genes Gli1 and 
Ptch1 in both WT and Gli1lacZ/+ fibroblasts following treatment with Cos7-ctrl 
or Cos7-Shh conditioned media. qRT-PCR analysis for cytokines (C) IL-6, 
(D) Mcp-1, (E) mIL-8, and (F) M-csf in both WT and Gli1LacZ/+ fibroblasts 
following treatment with control (Ctrl) or cancer-cell conditioned media 
(CCM). 
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Figure 3.14: Identification of Gli1 target genes.  
(A) Experimental design. (B) qRT-PCR analysis for HH target genes Gli1 and 
Ptch1, and the cytokines Mcp-1, M-Csf, IL-6, and mIL-8 in NIH3T3 cells 
following treatment with Cos7-ctrl or Cos7-Shh conditioned media.  
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Figure 3.15: Identification of Gli1 binding sites.  
 (A) Putative GLI1 binding sites on cytokines’ 5’ region.  (B-E) Chromatin 
immunoprecipitation assay on putative GLI1 binding regions, (F) on positive control 
Cyclin D1, and (G) on a region lacking GLI1 binding sites as a negative control.  
 
(Data/Figure credit: Dr. Maite Fernandez-Barrena in the lab of Dr. Martin 
Fernandez-Zapico.)  
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Figure 3.16: Tissues with reduced Gli1 expression have altered immune 
infiltration 
(A) Flow cytometry analysis for CD45+ cells. (B) Immunohistochemistry for 
F4/80 macrophages in iKras* and iKras*Gli1lacZ/+ pancreata. Flow cytometry 
analysis for (C) macrophages (D) immature myeloid cells (E) 
polymorphonuclear-derived immature myeloid cells, and (F) mononuclear-
derived immature myeloid cells 
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Figure 3.17: Tissues with reduced Gli1 expression have altered immune 
infiltration 
Flow cytometry analysis for (A) CD3+ T cells (B) Helper T cells (C) Cytotoxic T cells, 
and (D) Regulatory T cells. (E) Correlation between Gli1 expression and immature 
myeloid cell infiltration in iKras*Gli1lacZ/+ pancreata.  Flow cytometry analysis for (F) 
M2 macrophages and (G) M1 macrophages. 
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Figure 3.18: Canonical Hh signaling is essential for pancreatic tissue repair 
following injury 
(A) H&E for p48Cre;Shhf/f pancreata either untreated or 2d and 1w following 
pancreatitis. Fibrotic areas are highlighted with black arrows. 
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Figure 3.19: Inhibition of HH signaling impairs pancreatic tissue repair 
following injury 
(A) Experimental Design (B) Quantitation of tissue repair (C) H&E (scale bars 
50µm), Gomori Trichrome (scale bars 50µm), SMA immunostaining (scale bars 
50µm), and pERK1/2 immunostaining (scale bars 50µm) for iKras* pancreata with 
Kras* active (Kras* ON) for 3w and subsequently inactivated (Kras* OFF) 2w. 
Mice were treated with vehicle or Smo antagonist LDE-225 during the 2 weeks 
following Kras* inactivation.  
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Figure 3.20: Canonical HH signaling is essential for cytokine 
secretion from pancreatic fibroblasts  
 (A) Experimental Design. (B) qRT-PCR analysis for cytokines IL-6, 
Mcp-1, mIL-8, and M-csf in WT pancreatic fibroblasts treated with 
cancer conditioned media (CCM) with and without concomitant HH 
inhibition.  
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Figure 3.21:  Working model of Gli1 regulation of pancreas remodeling 
following injury 
Following injury, pancreatic fibroblasts upregulate the expression of cytokines 
regulating myeloid cell recruitment and function. Gli1 dosage is critical for this 
response. Reduced Gli1 dosage leads to reduced cytokine expression and 
impaired recruitment of myeloid cells. Specifically, the recruitment of M2 
macrophages -the myeloid population critical for injury repair and tissue 
remodeling- is reduced. Ultimately, reduction in Gli1 dosage results improper 
pancreatic recovery.  
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Tables 
Table 3.1: Primer sequences 
Gene Forward (5’-3’) Reverse (5’-3’) 
TREKras caaggacaaggtgtacagttatgtgact gcctgcgacgcggcatctgc 
Gli1 gcagtgggtaacatgagtgtct aggcactagagttgaggaatttgt 
Ptch1 ttgtggaagccacagaaaacc tgtctggagtccggatgga 
Hhip1 gctctcgtttaagctgctactg caaacttcgcatctccttcaaag 
Gli2 gtgcacagcagccccacactctc ggtaatagtctgaagggttggtgcctgg 
Shh caaagctcacatccactgttctg gaaacagccgccggattt 
IL-6 ttccatccagttgccttcttgg ttctcatttccacgatttcccag 
Mcp-1 ttaaaaacctggatcggaaccaa gcattagcttcagatttacgggt 
IL-8 ctgcacccaaaccgaagtcat ttgtcagaagccagcgttcac 
M-csf gacttcatgccagattgcc  ggtggctttagggtacagg  
Cyclin D1 taggaaggagcctatcgtgtctca caacagctcaagatggtggccatt 
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CHAPTER FOUR 
Mesenchymal Stem Cells promote pancreatic tumor growth by promoting M2 
macrophage polarization1 
 
Abstract 
Pancreatic cancer is characterized by an extensive desmoplastic stroma, the 
functional relevance of which is poorly understood. Activated fibroblasts are a prevalent 
component of the stroma and traditionally, these cells have been considered as a 
homogenous population derived from pancreatic stellate cells. In this study, we highlight 
a previously unappreciated heterogeneity of the fibroblast population within the stroma.  
In particular, a subset of stromal fibroblasts have characteristics of Mesenchymal Stem 
Cells (MSCs). MSCs are present in the normal pancreas (P-MSCs), as well as in the 
carcinomatous pancreas (CA-MSCs). Here, we determine that CA-MSCs have 
increased tumor-promoting function compared with P-MSCs. This ability to promote 
tumor growth is associated with CA-MSCs’ unique ability to promote alternative 
macrophage polarization.  Thus, our study identifies a previously uncharacterized cell 
                                                          
1 Manuscript currently in review at Cancer Discovery. Mathew, E., Brannon, A.L., Del Vecchio, 
A., Penny, M.K., Kane, K.T., Vinta, A., Buckanovich, R.J., and Pasca di Magliano, M. Tentative 
Title: Mesenchymal Stem Cells promote pancreatic tumor growth by promoting M2 macrophage 
polarization. 
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population within the stroma and sheds light on tumor-promoting interactions between 
different components of the stroma.  
Introduction  
Pancreatic cancer is among the deadliest of human malignancies. A prominent 
feature of pancreatic cancer is an extensive reactive stroma, which can comprise up to 
90% of the overall tumor volume, the highest fraction of all solid, epithelial tumors (for 
review, see (1)). The accumulation of a desmoplastic stroma occurs from the onset of 
pancreatic carcinogenesis, and is evident in the precursor lesions of pancreatic cancer 
known as pancreatic intraepithelial neoplasia or PanINs (2). The cellular components of 
the stroma include fibroblasts, myofibroblasts, endothelial cells and infiltrating immune 
cells (3,4). Fibroblasts are an abundant and poorly characterized component of the 
stroma, thought to derive from pancreatic stellate cells.  Fibroblasts within the stroma 
have been thought of as pro-tumor agents (5), but recent studies have challenged this 
concept indicating that stromal fibroblasts might act of restrain tumor growth (6,7). This 
controversy might in part reflect our limited understanding of cellular components of the 
stroma and their individual contribution to tumorigenesis. 
  The healthy pancreas includes different fibroblast populations. A population of 
mesenchymal stem cells (P-MSCs) was identified in the normal human and mouse 
pancreas (8-10); however, whether MSCs are present in pancreatic carcinoma and 
what their function might be during carcinogenesis remained unclear. MSCs were 
identified as a tumor-promoting stromal component in several epithelial cancers (11-13). 
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Interestingly, the manner in which MSCs promote tumorigenesis is distinct in each 
tumor context. In breast cancer, bone marrow derived MSCs promote the metastasis of 
tumor cells through a CCL5-mediated effect (12).  In ovarian cancer, MSCs isolated 
from the tumor stroma secrete BMPs that increase the cancer stem cell population (13). 
More recently, stroma-derived MSCs from lymphomas have been shown to secrete 
monocyte/macrophage chemoattractants, which in turn promote tumor growth (14).  
The identification and characterization of MSCs in pancreatic tumor growth is the 
focus of the current study. We use a genetically engineered mouse model of pancreatic 
cancer, the KC mouse (Ptf1a-Cre;LSL-KrasG12D) (15) that expresses an oncogenic form 
of Kras, mirroring the most common genetic alteration in human PanINs and pancreatic 
cancer (16,17). KC mice develop PanINs in a step-wise manner that recapitulates 
human carcinogenesis (15). Our results show that MSC populations are present both in 
the normal murine pancreas (pancreatic MSCs, P-MSCs), and neoplastic mouse 
pancreas (carcinogenesis-associated MSCs, CA-MSCs).  By performing functional 
comparisons of these two populations, we determined that CA-MSCs have an increased 
tumor-promoting potential, which is mediated, at least in part, by their unique ability to 
induce macrophage polarization to a pro-tumor, M2-like status.  
Materials and Methods 
Mice 
Mice were housed in specific pathogen-free facilities of the University of Michigan 
Comprehensive Cancer Center. This study was approved by the University of Michigan 
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University Committee on Use and Care of Animals (UCUCA) guidelines. Ptf1a-Cre;LSL-
KrasG12D (KC) animals were generated by crossing Ptf1a-Cre mice (18) with LSL-
KrasG12D (15). Acute pancreatitis was induced as previously described (19) by two 8-
hourly series of intraperitoneal injections with caerulein (Sigma) at a concentration of 
75ug/kg over a 48-hour period.  
Cell Culture 
All cells were cultured in IMDM supplemented with 10% FBS and 1% 
penicillin/streptomycin (Gibco). Primary mouse pancreatic fibroblasts were derived from 
control or KC pancreata. Pancreata were minced with sterile scissors and subsequently 
digested in 1mg/mL collagenase. MSCs were sorted from cultures using Fluorescence 
Activated Cell Sorting as described below. For bone marrow MSC extraction, the tibia 
and femur was flushed with culture media. Collected marrow was plated after being 
extruded through a 20 G syringe to disassociate tissue.  After 2 days, cultures were 
washed twice with PBS and adherent cells cultured for an additional week prior to 
FACS.  Primary MSCs were verified using both flow cytometry for defined markers as 
well as functional testing of differentiation capacity into bone and fat. MSC differentiation 
was verified up to passage 10, and all experiments were performed on MSCs below this 
passage number. For MSC differentiation experiments, cells were plated following 
instructions on commercially available differentiation kits for osteogenesis, 
chondrogenesis, and adipogenesis (all Gibco). Bone-marrow derived macrophages 
were derived using an established protocol (20). Briefly, extruded bone marrow 
precursors were cultured in one week in growth media supplemented with 20% L929 
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conditioned media, 10% FBS, and 1% pen/strep. For RAW264.7 polarization 
experiments, neutralizing antibodies in PBS were used at indicated concentrations to 
block IL10 (R&D Systems #AF519) and IL6 (R&D Systems #MAB406).  
Reverse Transcription Real-Time Quantitative PCR (RT-qPCR)  
Cells for RNA extraction were collected in lysis buffer (Ambion). RNA was isolated using 
a PureLink RNA Mini Kit (Ambion) as per manufacturer instructions. Reverse 
transcription was conducted with a High-Capacity cDNA Reverse Transcription Kit 
(Applied Biosystems). RT-qPCR reactions were prepared with 1x SYBR Green PCR 
Master Mix (Applied Biosystems) and primers  (Table 4.1) were optimized for 
amplification under the following reaction conditions:  95°C 10 minutes, followed by 40 
cycles of 95°C 15 seconds and 60°C 1 minute.  Melt curve analysis was included in the 
amplification protocol for all samples. Ppia (Cyclophilin A) and Gapdh were used as 
control housekeeping genes.  
Western Blot 
Protein was isolated from Raw264.7 cells in lysis buffer (50mM Tris pH 8.0, 1% Triton 
X-100, 130mM NaCL, 1mM Na3VO4*, 10mM Na4P2O7, 10mM NaF, 1mM EDTA). 
Equal amounts of protein were electrophoresed in SDS-PAGE gels and transferred to 
PVDF membranes (Bio-Rad). The following primary antibodies from Cell Signaling 
Technologies were used: AKT (1:1000, Cat# 9272), pAKT (Ser473) (1:1000, Cat# 
9271), ERK (1:1000, Cat# 9102), pERK (Thr202/Tyr204) (1:1000, Cat# 9101), RalA 
(1:2500, Cat# 3526), STAT3 (1:1000, Cat# 9139), pSTAT3 (Tyr705) (1:1000, Cat# 
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9131). The following horseradish peroxidase-conjugated secondary antibodies from Bio-
Rad were used (1:5000): Goat Anti-Mouse (Cat# 1721011) and Goat Anti-Rabbit (Cat# 
1706515). Individual protein bands were visualized using Western Lightning Plus 
Enhanced Chemiluminescence (PerkinElmer, Cat# NEL103001EA) and film.  
Flow Cytometry 
Single cell suspensions were prepared from the pancreas as follows: tissues were 
minced with sterile scalpels prior to digestion in 1mg/mL collagenase (Sigma-Aldrich) at 
37C for 15min. Digested samples were then filtered through a 40m strainer. Single 
cell suspensions were prepared in HBSS with 2% FBS for Fluorescence activated cell 
sorting  (FACS). Antibodies used for MSCs were CD44-FITC (1:50, BD Pharm), CD73-
PeCy7 (1:50, ebioscience), CD49a-PE (1:50, BD Pharm), and CD90-APC (1:50, BD 
Pharm). Antibodies used for immune cells were CD45-Pacific Orange (1:50, BD 
Pharm), CD11b-APCCy7 (1:50, BD Pharm), CD3-PE (1:50, BD Pharm), F4/80-PECy5 
(1:50, ebioscience), CD64-PE (1:50, BD Pharm). FACS was performed on a MoFlo 
Astrios (Beckman Coulter) and data analyzed using Summit 6.1 Software.  
Immunohistochemistry and Immunofluorescence  
Primary antibodies used were CK19 (1:100, Iowa Developmental Hybridoma Bank), 
F4/80 (1:100, BMA Biomedicals), Ki67 (1:100, Vector Laboratories), Cleaved Capsase 3  
(1:300, Cell Signaling). Images were taken with an Olympus BX-51 microscope, 
Olympus DP71 digital camera, and CellSens standard v1.6 software. For 
immunofluorescence, Alexa Fluor-conjugated (Invitrogen) secondary antibodies were 
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used. Cell nuclei were counterstained with Prolong Gold-DAPI (Invitrogen). The images 
were acquired using an Olympus IX-71 confocal microscope and FluoView FV500/IX 
software.  
Statistical Analysis 
Student's t-tests were used to compare experimental cohorts, and significance was 
established for p-values < 0.05. Significance values indicated by asterisks or pound 
signs are as follows: *p<0.05, **p < 0.01, ***p < 0.0005, ****p < 0.0001 
Results 
MSCs are Present in the Normal and in the Neoplastic Pancreas  
MSCs are defined by their ability to differentiate into osteoblasts, chondrocytes, 
and adipocytes when exposed to appropriate differentiation media in vitro. To test 
whether we could identify a MSC population in the normal and neoplastic murine 
pancreas, we isolated pancreata from wildtype and littermate KC mice 3 weeks after the 
induction of acute pancreatitis. Wildtype pancreata have completed the tissue repair 
process by this time, whereas in KC pancreata, extensive PanINs surrounded by 
desmoplastic stroma are evident (Figure 4.1A) (15). Isolated bulk fibroblast populations 
from the pancreata were exposed to osteoblast, adipocyte and chondrocyte 
differentiation media. Tri-lineage differentiation was observed in the wildtype and in the 
KC-derived pancreata, indicating that a MSC population might exist in both settings 
(Figure 4.1B).  MSCs have been isolated based on the expression of a panel of surface 
markers: CD45-;CD44+;CD49a+:CD73+;CD90+ (21).  To determine whether these 
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markers were sufficient to isolate the MSC population in the pancreas, we isolated 
single-cell suspensions from wildtype and KC pancreata, 3 weeks after the induction of 
pancreatitis, and used fluorescent-activated cell sorting (FACS) to isolate and quantify 
cells expressing MSC markers. While CD45-;CD44+;CD49a+:CD73+;CD90+cells were 
present in both sample sets, their number was significantly higher in KC pancreata 
compared to the normal mouse pancreas (Figure 4.2A). To determine whether the 
surface markers did indeed identify the MSC population, we cultured 
CD44+;CD49a+:CD73+;CD90+ cells (putative MSCs, 4+) as well as cells negative for all 
markers (4neg) and performed in vitro differentiation assays with protocols promoting 
osteoblast and adipocyte lineages. In differentiation media, CD45-
;CD44+;CD49a+:CD73+;CD90+ cells from both the normal and neoplastic pancreas 
could differentiate into osteoblasts -as determined by Alizarin Red staining of calcium 
deposits, and expression of the osteoblast marker Alkaline Phosphatase (Figure 4.2B 
and 4.2C, top row) - and adipocytes -as determined by Oil Red O staining of lipid 
droplets and expression of adipocyte marker Fatty acid binding protein 4 (Fabp4) 
(Figure 4.2B and 4.2C, bottom row). In contrast, 4neg cells did not differentiate into any 
of the lineages (Figure 4.2B and 4.2C), indicating that the combination of CD44+, 
CD49a+, CD73+ and CD90+ surface markers identifies a subset of multipotent cells.  
CA-MSCs have a Distinct Cytokine Expression Profile.  
Since MSCs were present both in the normal and in the neoplastic pancreas, we 
set out to compare their functional characteristics. Hereby, normal pancreas-derived 
MSCs are referred to as P-MSCs, while MSCs derived from the neoplastic pancreas are 
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referred to as CA-MSCs (carcinoma-associated MSCs). In ovarian cancer, CA-MSCs 
are distinct from bone marrow and adipose-derived MSCs by the expression of BMP2 
and BMP4, and those factors confer a higher tumor-promoting ability to CA-MSCs (13). 
Thus, we measured the relative expression of BMP2 and BMP4 by qRT-PCR in isolated 
P-MSCs and CA-MSCs.  We detected no difference in BMP2 expression, while BMP4 
expression was decreased in CA-MSCs compared to P-MSCs (Figure 4.2D).  
We have previously shown that pancreatic fibroblasts secrete a number of 
cytokines that regulate the infiltration of immune cells during pancreatic damage and 
repair and during carcinogenesis (22).  Thus, we measured expression of those 
cytokines by qRT-PCR in freshly sorted P-MSCs and CA-MSCs. Interestingly, we 
observed a significant increase in several cytokines known to promote tumorigenesis, 
including IL6, IL10, and TGFβ (23-27) in CA-MSCs compared with P-MSCs (Figure 
4.3A). Then, we measured the expression of the same subset of cytokines in cultured 
CA-MScs and P-MSCs, respectively, and found a similar profile, with significantly 
elevated cytokines in CA-MSCs (Figure 4.3B). Similarly M-CSF (Csf1) and GM-CSF 
(Csf2), cytokines known to regulate immune cell recruitment and function, were 
significantly elevated in CA-MSCs compared with P-MSCs. Finally, we compared paired 
bone marrow and pancreatic MSCs extracted from a control mouse (P-BM MSCs and 
P-MSCs) or a PanIN-bearing KC mouse (CA-BM MSCs and CA-MSCs). P-MSCs 
expressed higher levels of IL6, Cox-2, and IL10 than their bone marrow counterparts.  
CA-MSCs expressed higher levels of IL6, Cox-2, TGFβ, and IL10 than both P-MSCs 
and CA-BM MSCs (Figure 4.4). These data indicate that MSCs extracted from the 
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neoplastic pancreas have unique characteristics, that are not shared by their 
counterpart extracted from the normal organ nor by MSCs extracted by different organs 
(in this case, the bone marrow) of a mouse bearing neoplastic changes in the pancreas.  
MSCs Promote Pancreatic Tumor Growth  
To determine the functional effect of MSCs on tumor growth, we performed 
subcutaneous co-injections of tumor cells and MSCs into immunocompetent mice using 
a syngeneic littermate approach. We used tumor cells isolated from the iKras*p53* 
mouse model (28) of pancreatic cancer (cell line: iKras*p53*#3 (29)). Tumor cells were 
injected at a 1:1 ratio with either P-MSCs or CA-MSCs (see schematic in Figure 4.5A). 
Co-injection of P-MSCs with iKras*p53*#3 cells promoted tumor growth, but co-injection 
with CA-MSCs promoted even larger tumor growth (Figure 4.5B). The histology of all 
three cohorts was similar with epithelial structures surrounded by abundant stroma 
(Figure 4.5C). Staining for CK19 to mark tumor cells revealed increased number of 
tumor cells in co-injections with CA-MSCs (Figure 4.6A). Consistently, we detected 
increased intratumor proliferation -as indicated by Ki67 staining- in co-injections with 
CA-MSCs. Immunofluorescence analysis revealed a notable increase in proliferating 
tumor CK19+ cells, indicating an increase in proliferating tumor cells (Figures 4.6B and 
4.6C).   
Given our previous observation that CA-MSCs secreted a number of cytokines 
that are known to regulate macrophages, we sought to determine the effect of MSC co-
injection on macrophage infiltration within the tumor. Thus, we stained tissues for F4/80, 
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a mature macrophage marker. We detected a significant increase in macrophages in 
the tumors derived from co-injection of tumor cells and CA-MSCs compared to tumor 
cells alone or co-injected with P-MSCs (Figure 4.5C, inset). To quantify macrophage 
numbers in the subcutaneous tumors, we performed flow cytometry for macrophages 
defined as CD11b+;CD64+;F4/80+ cells. We found that tumors derived from the CA-MSC 
co-injection consistently had the highest population of macrophages compared to the 
other experimental cohorts, thus corroborating the histology (Figures 4.5C, inset, and 
4.6D).   
We repeated these experiments using tumor cells derived from the KPC mouse 
model (30) of pancreatic cancer (cell line: 13442) (see schematic in Figure 4.7A). 
Similar to co-injections with iKras*p53*#3 cells, CA-MSCs promoted the growth of larger 
tumors than P-MSCs (Figure 4.7B). Although overall histology was comparable 
between experimental cohorts (Figure 4.7C), increased intratumoral proliferation 
(Figures 4.7D and 4.7E) and macrophage infiltration (Figures 4.7C, inset and 4.7F) 
was again detected in tumors co-injected with CA-MSCs.  
To determine whether MSCs were still able to promote tumor growth when 
injected at a lower ratio, we performed a parallel set of experiments by injecting tumor 
cells (13442) and MSCs at a 2:1 ratio.  We found that at this lower ratio P-MSCs were 
unable to promote tumor growth, while in contrast CA-MSCs still promoted tumor 
growth, further validating the concept that CA-MSCs have increased tumor-promoting 
ability (Figure 4.8A). 
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Since our data indicated that CA-MSCs have different functional characteristics 
than P-MSC, we expanded our characterization to include bone-marrow derived MSCs 
(BM-MSCs). In the absence of rigorous lineage tracing studies, it is not known whether 
CA-MSCs derived from P-MSCs or, at least in part, from infiltrating BM-MSCs, as 
observed in other disease contexts (31,32). This is a question that warrants further 
studies that are beyond the scope of the current manuscript. BM-MSCs from a control 
mouse promoted tumor growth similarly to P-MSCs. However, CA-MSCs were able to 
promote significantly more tumor growth than their bone-marrow derived counterparts 
(Figures 4.8B and 4.8C). Thus, CA-MSCs have a unique tumor promoting ability; we 
then set out to understand the mechanistic basis for this finding.   
Monocyte migration to the tumor stroma and subsequent differentiation into 
macrophages is a process orchestrated by an array of signaling molecules. To assess 
potential differences in these cytokine levels between tumor cohorts, we collected RNA 
from subcutaneous tumor tissue for RT-qPCR analysis. We found that expression of 
Mcp-1, a potent monocyte chemoattractant, did not differ between tumors co-injected 
with P-MSCs or with CA-MSCs but, at least for tumors derived from the 13442 line, was 
higher in the MSC-co-injected tumors than in the control group (Figures 4.9A and 
4.9C). Interestingly, we detected an increase in M-CSF in co-injections with CA-MSCs 
(Figures 4.9B and 4.9D), a cytokine that supports the differentiation of monocytes into 
macrophages.  
MSCs require Monocytes/Macrophages to Promote Tumor Growth 
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Macrophages have been shown to promote pancreatic growth (33). Thus, based 
on the observation that CA-MSCs promoted the highest infiltration of macrophages, we 
next tested whether this population’s elevated tumor-promoting potential required 
macrophages. Thus, we co-injected tumor cells and MSCs into immunocompetent mice 
with concomitant depletion of monocytes and macrophages. Cd11b-DTR mice express 
the human diphtheria toxin receptor under the Cd11b promoter (Figure 4.10A). 
Administration of diphtheria toxin (DT) to Cd11b-DTR mice depletes all CD11b+ cells, 
including monocytes/macrophages (34).  We performed a series of co-injection 
experiments with iKras*p53*#3 cells alone or in combination with P-MSCs or CA-MSCs. 
In a subset of each cohort, mice were injected with DT (Figure 4.10B). We found that 
tumor size was reduced by depleting CD11b+ cells in all experimental cohorts, 
underscoring the importance of myeloid cells in tumor growth. However, co-injections of 
iKras*p53*#3 cells with CA-MSCs were significantly more susceptible to myeloid cell 
ablation than any other experimental cohort,  in terms of tumor mass changes (Figure 
4.10C). We confirmed DT-mediated depletion by staining tumor tissues for F4/80; in all 
cohorts, DT administration significantly attenuated macrophage infiltration (Figure 4.11, 
inset).   While the tumor histology remained similar (Figure 4.11), immuno-staining for 
Ck19 revealed a reduction in the ratio of epithelial cells within the tumors (Figure 4.12). 
Moreover, while tumors derived from co-injections with CA-MSCs are more proliferative 
than the other cohorts, this increase in proliferation was abrogated upon myeloid cell 
depletion (Figure 4.13).  
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To determine whether the dependence on myeloid cells for tumor promotion was 
a unique property of CA-MSCs, or rather a common feature of fibroblasts derived from 
the neoplastic pancreas, we performed parallel co-injection experiments with non-MSCs 
(CD45-;CD44-;CD49a-:CD73-;CD90-) cells sorted from the neoplastic stroma (CA-non 
MSCs) (see schematic in Figure 4.14A). While these cells also promoted tumor 
growth, the extent of tumor mass reduction upon CD11b+ cell depletion was 
significantly less than in co-injections with MSCs (Figure 4.14B). Thus, CA-MSCs have 
a unique dependence on myeloid cells, which led us to investigate the interaction 
between these cell types.    
MSCs Promote Macrophage Differentiation and Polarization to a M2 Subtype 
In order to interrogate whether MSCs directly regulate macrophage polarization 
we investigated their interactions in vitro. First, we investigated whether CA-MSCs 
promote the differentiation of monocytes into macrophages. For this purpose, we 
isolated and cultured mouse bone marrow precursors. After 1 week of culture in regular 
medium, about 25% of the cell population differentiates to macrophages, defined as 
CD11b+;CD64+;F4/80+  cells by flow cytometry. As expected based on previous studies 
(20), exposure to M-CSF supplemented media led to differentiation of a uniform 
population of CD11b+;CD64+;F4/80+ macrophages (Figure 4.15).  We tested the effect 
of supplementing the culture medium with conditioned media from either P-MSCs or 
CA-MSCs, as well as P-nonMSCs and CA-nonMSCs (pancreatic fibroblasts or 
neoplastic fibroblasts).  Both P-MSCs and CA-MSCs promoted macrophage 
differentiation in over 50% of the bone marrow precursors, with no significant difference 
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between the two populations. In contrast, only non-MSC fibroblasts from the neoplastic 
pancreas could also promote macrophage differentiation, although to a lesser extent 
than their MSC counterparts (Figure 4.15).  
 We next assessed whether P-MSCs or CA-MSCs regulated macrophage 
polarization.  First, we performed RT-qPCR analysis for M1 and M2 markers on RNA 
collected from our subcutaneous co-injection experiments (Figures 4.16A and 4.16B).  
We found that tumors derived from co-injection with both P-MSCs and CA-MSCs had 
decreased expression of iNos, a M1 marker, compared with tumor cells injected alone. 
However, only co-injections with CA-MSCs tumor cells showed increased expression of 
Arg1 and CD206, both M2 markers. Likewise, the expression of IL10 – a cytokine 
known to regulate M2 differentiation- was significantly increased in co-injections with 
CA-MSCs (Figures 4.16A and 4.16B).  Importantly, these changes were observed both 
with iKras*p53* and KPC tumor cells.  
To test whether MSCs directly regulated macrophage polarization to a M2 
phenotype, we treated three independently derived cultures of bone marrow derived 
macrophages (BMDMs) with conditioned media from either P-MSCs or CA-MSCs for 12 
hours (see schematic in Figure 4.17A).  We found that both P-MSCs and CA-MSC-
conditioned medium decreased iNOS expression in BMDMs compared with control 
medium, indicating suppression of the M1 subtype. However, only CA-MSC-conditioned 
medium promoted M2 polarization, as determined by Arg1 expression (Figure 4.17B).  
We then repeated this set of experiments using the mouse macrophage cell line 
RAW264.7 that can be polarized in culture.  Conditioned media from P-MSCs had no 
142 
 
effect on the expression of iNos or Arg1 in macrophages. In contrast, while conditioned 
media from CA-MSCs stimulated a four-fold increase in iNos expression, Arg1 
expression was increased over one hundred-fold. We also tested the effect of 
conditioned media from bone marrow MSCs, which have been reported to stimulate M2 
macrophage polarization and Arg1 expression in macrophages (35,36).  We found that 
while CA BM-MSCs could promote Arg1 expression, this effect was significantly less 
than CA-MSCs (Figure 4.17C).  Taken together, our data indicates that the ability to 
promote M2-like macrophage polarization is restricted to CA-MSCs.   
As CA-MSCs expressed significantly higher IL6 and IL10 compared to P-MSCs, 
and these cytokines are known to regulate macrophage polarization, we tested whether 
production of these cytokines explained the unique ability of CA-MSCs to promote M2 
polarization.  Thus, we treated RAW264.7 macrophages with CA-MSC conditioned 
media with and without an IL6 neutralizing antibody or an IL10 neutralizing antibody and 
assessed Arg1 expression.  Consistent with IL6 stimulation, CA-MSC conditioned 
medium increased pSTAT3 levels in RAW264.7 macrophages compared to control 
medium, and this increase was abrogated by the anti-IL6 antibody but not by the anti-
IL10 antibody (Figure 4.18A). Treatment with CA-MSC conditioned medium induced 
Arg1 expression in RAW264.7 macrophages; this induction was partially abrogated by 
anti-IL6 and, to a lesser extent, by anti-IL10 treatment (Figure 4.18B). Concomitant 
treatment with anti-IL6 and anti-IL10 antibodies completely blocked the induction of 
Arg1 expression, indicating that these two cytokines might act along parallel, non 
overlapping paths (Figure 4.18B). We then investigated the effect of CA-MSC 
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conditioned medium on the expression of M1 differentiation markers. We observed no 
change in iNOS expression, but a reduction of IL12p35 upon treatment with conditioned 
medium (Figures 4.19A and 4.19B).  This decrease was reversed with higher 
concentrations of either IL6 or IL10 inhibition (Figures 4.19B). Taken together, our 
results show that both P-MSCs and CA-MSCs can induce macrophage differentiation 
for a precursor population, but only CA-MSC specifically direct polarization to a tumor 
promoting M2-like subtype.  
Discussion 
Fibroblasts exist in every tissue and organ in the body and are a prevalent 
population within the pancreatic cancer stroma.  Our understanding of their functional 
specificity, however, remains limited. Here, we have identified a sub-population of 
fibroblasts present both within the normal pancreas and in the neoplastic pancreas, with 
MSC characteristics, namely the ability to differentiate into chondrocytes, adipocytes 
and osteoblasts. We determined that MSCs from the neoplastic pancreas (CA-MSCs) 
have a unique ability to promote tumor growth, that depends on their ability to promote 
infiltration of monocytes/macrophages and their differentiation to a M2, tumor 
promoting, phenotype (Figure 4.20).   Our study highlights the functional heterogeneity 
of stromal fibroblast populations, and the different functional properties of fibroblasts 
derived from the normal or neoplastic organ.  Further, our study identifies novel 
interactions between the fibroblast population and the immune component of pancreatic 
cancer.  
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Figures 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.1: Mesenchymal Stem Cells (MSCs) are present in the pancreas  
(A) H&E staining of wildtype (left) and KC (right) pancreas 3w post-caerulein-
induced pancreatitis. Scale bar, 50µm. (B) Stromal cells isolated from the 
neoplastic pancreas can differentiate into osteoblasts (top row), chondrocytes 
(middle row), and adipocytes (bottom row).  
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Figure 4.2: MSCs can be sorted from the normal and neoplastic pancreas  
(A) Flow cytometry analysis of MSC populations in the wildtype and KC pancreas. (B) 
MSCs sorted from the normal pancreas (P-MSCs) can differentiate into bone (top row) 
and fat (bottom row) (C) MSCs sorted from the neoplastic pancreas (CA-MSCs) can 
differentiate into bone (top row) and fat (bottom row) (D) qRT-PCR for BMP2 and BMP4 
on MSCs freshly sorted from the pancreas.  
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Figure 4.3: Differences in cytokine expression between MSCs from the 
normal and neoplastic pancreas 
(A) qRT-PCR for IL-6, Cox-2, IL-10 and TGFβ-1 on MSCs freshly sorted from the 
pancreas. (B) Expression of IL-6, Cox2, Tgfβ1, M-csf, Gm-csf, and G-csf in MSCs 
cultured in vitro.  
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Figure 4.4: Differences in MSCs from the bone marrow and pancreas. 
(A) Expression of Il6, Cox2, Tgfβ1, and Il10 in bone marrow and pancreatic 
MSCs.   
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Figure 4.5: CA-MSCs promote tumor growth when co-injected with 
iKras tumor cells.  
(A) Experimental design. (B) Gross tumor morphology and final tumor 
mass. Scale bar represents 0.5cm. (C) Histopathological analysis of 
tumors following co-injection. H&E staining, Scale bar represents 50μm. 
Inset F4/80 staining, scale bar represents 50μm.  
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Figure 4.6: CA-MSCs promote tumor proliferation and macrophage 
infiltration.  
(A) Immunohistochemistry for Ck19, scale bar represents 20μm. (B) 
Immunohistochemistry for Ki67 (green) and Ck19 (red), scale bar 
represents 20μm. (C)Quantitation of Ki67 staining. (D) Flow cytometry 
analysis of macrophages.  
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Figure 4.7: CA-MSCs promote tumor growth when co-injected with KPC 
tumor cells.  
(A) Experimental design. (B) Final tumor mass. (C) Histopathological analysis 
of tumors from co-injection of 13442 KPC tumor cells with MSCs, scale bar: 
50μm. Inset: antibody detection of F4/80. Scale bar: 20μm. (D) Antibody 
detection of Ki67, scale bar: 20μm. Inset: antibody detection of Ki67 (green) 
and CK19 (red). Nuclei marked by DAPI (blue), scale bar: 20μm. (E) 
Quantitiation of Ki67 staining. (F) Flow cytometry analysis of tumor 
CD11b+;CD64+;F4/80+ macrophages.  
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Figure 4.8: CA-MSCs promote tumor growth compared to their bone marrow 
counterparts.  
(A) Final tumor mass for 13442 KPC tumor cells co-injected with MSCs at 2:1 and 
1:1 ratios. (B) Final tumor mass of iKras*p53*#3 tumor cells co-injected with 
pancreatic and bone marrow MSCs.  (C) Final tumor mass of 13442 KPC tumor 
cells co-injected with pancreatic and bone marrow MSCs.   
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Figure 4.9: Tumors co-injected with CA-MSCs express the 
highest levels of Mcp-1.  
qRT-PCR analysis for (A) Mcp-1 and (B) M-csf in subcutaneous 
co-injection experiments with iKras*p53#3 cell line and MSCs. 
qRT-PCR analysis for (C) Mcp-1 and (D) M-csf in subcutaneous 
co-injection experiments with 13442 cell line and MSCs.  
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Figure 4.10: Myeloid cells are vital for CA-MSC-mediated tumor growth.  
(A) Schematic for Cd11b-DTR mouse. (B) Experimental Design. (C) Left: Final 
tumor mass. Data is presented as mean ± SEM. Right:  Percentage decrease in 
tumor mass.  
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Figure 4.11: Myeloid cells can be depleted from tumors in CD11b-DTR mice.  
(A) Histopathological analysis of tumors following co-injection. H&E staining, 
Scale bar represents 50μm. Inset F4/80 staining, scale bar represents 50μm. 
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Figure 4.12: Tumor cell numbers are reduced upon myeloid cell 
depletion.  
(A) Antibody detection of CK19, scale bar: 20μm. 
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Figure 4.13: Myeloid cell depletion reduces the number of proliferating 
cells in tumors.  
(A) Immunohistochemistry for Ki67, scale bar represents 20μm. 
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Figure 4.14: Myeloid cell depletion reduces tumor size.  
(A) Experimental design. (B) Percent change in tumor mass after CD11b cell 
depletion. 
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Figure 4.15: CA-MSC derived factors promote macrophage 
differentiation.  
(A) Flow cytometry analysis of in vitro differentiated 
macrophages. Each data point represents bone marrow 
precursors from one mouse. 
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Figure 4.16: Tumor tissue from CA-MSCs co-injected with tumor cells express 
markers of M2-like macrophage polarization.  
(A) RT-qPCR analysis of tumor tissue from co-injections of iKras*p53*#3 tumor cells 
with MSCs for iNos, Arg1, Cd206, Il-10. (B) RT-qPCR analysis of tumor tissue from co-
injections of 13442 KPC tumor cells with MSCs for iNos, Arg1, Cd206, Il-10. 
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Figure 4.17: CA-MSC derived factors promote M2-like macrophage 
polarization in vitro.  
(A) Experimental design. (B) qRT-PCR on BMDMs for iNOS (left) and 
Arg1 (right). Each data point represents BMDMs from one mouse. (C) 
qRT-PCR on Raw264.7 macrophages for  iNOS (left) and Arg1 (right).  
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Figure 4.18: CA-MSC derived IL6 and IL10 promote M2-like macrophage 
polarization.  
(A) Western Blot analysis of RAW264.7 macrophages treated with conditioned 
media and inhibitors. (B) qRT-PCR on RAW264.7 macrophages treated with 
conditioned media and inhibitors for Arg1. # indicate significant differences 
from CA-MSC stimulated cells.  
Figure 4.17A Data/figure credit: Arthur L. Brannon and AnnaChiara Del 
Vecchio.  
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Figure 4.19: CA-MSC derived IL6 and IL10 suppress M1-
like macrophage polarization.  
(A) RT-qPCR analysis of RAW264.7 macrophages for iNos. 
(B) RT-qPCR analysis of RAW264.7 macrophages for 
IL12p35. # indicate significant differences from CA-MSC 
stimulated cells. 
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Figure 4.20: Working model wherein CA-MSC derived 
IL6 and IL10 promote M2-like macrophage polarization, 
which in turn promotes tumor growth.  
Working model: CA-MSCs promote tumor growth, in part, 
by supporting the recruitment and polarization of M2-like 
macrophages.   
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Tables 
Table 4.1: List of primers 
Primer Forward (5’-3’) Reverse (5’-3’) 
Arg1 
ctccaagccaaagtccttagag aggagctgtcattagggacatc 
 
BMP2 gggacccgctgtcttctagt tcaactcaaattcgctgaggac 
BMP4 ttcctggtaaccgaatgctga cctgaatctcggcgacttttt 
CD206 
ggcaggatcttggcaacctagta gtttggatcggcacacaaagtc 
 
Cox-2 tgagcaactattccaaaccagc gcacgtagtcttcgatcactatc 
G-CSF atggctcaactttctgcccag ctgacagtgaccaggggaac 
GM-CSF atgcctgtcacgttgaatgaag gcgggtctgcacacatgtta 
IL6 ttccatccagttgccttcttgg ttctcatttccacgatttcccag 
IL10 
gctcttactgactggcatgag cgcagctctaggagcatgtg 
 
IL12p35 
cctcagtttggccagggtc caggtttcgggactggctaag 
 
iNOS 
ccaagccctcacctacttcc ctctgagggctgacacaagg 
 
M-CSF gacttcatgccagattgcc ggtggctttagggtacagg 
Mcp-1 ttaaaaacctggatcggaaccaa gcattagcttcagatttacgggt 
TGFβ1 tgacgtcactggagttgtacgg ggttcatgtcatggatggtgc 
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Chapter Five1 
Future Directions 
Pancreatic cancer has the highest accumulation of reactive stroma of all solid 
epithelial cancers; up to 90% of the bulk tumor can consist of stromal elements, and as 
little as 10% the tumor cells themselves (1).  Adding further complexity to this disease, 
the various components of the reactive stroma, from fibroblasts to various immune cells, 
respond to signals from the tumor, and also signal to each other. The molecular 
crosstalk between the tumor and stroma as well as from cells of the stroma to each 
other profoundly impacts tumorigenesis. Understanding the nature of these various 
molecular conversations is an area of active investigation, with the hope of identifying 
pathways of therapeutic significance. My thesis work focused on the contribution of 
stromal components to pancreatic tumorigenesis and pancreatic repair, with a particular 
emphasis on the HH pathway. 
The role of dosage-dependent HH signaling on pancreatic cancer  
Tumor growth  
                                                          
1 Portions of this chapter have been submitted as an invited review to Cellular and 
Molecular Life Sciences: Mathew, E, Allen BA, and Pasca di Magliano, M. Tentative 
title: Hedgehog Signaling in Pancreatic Cancer 
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The work in Chapter Two highlighted a dosage-dependent role of HH signaling 
on promoting tumor growth. By deleting two (Gas1 and Boc) or three (Gas1, Boc, and 
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Cdon) HH co-receptors in fibroblasts, I was able to reduce their HH-
responsiveness moderately or almost completely, respectively. Further, I used these 
fibroblasts to reveal a dosage dependant effect of HH-response on tumor promotion; 
fibroblasts with little or no HH-response did not promote tumor growth, but 
counterintuitively, fibroblasts with a moderate response to HH promoted the growth of 
large, vascular tumors (2). However, my data as presented did not exclude the possible 
role of CDON for mediating the tumor-promoting effect. While further experiments are 
needed on multiple, independent MEF lines, initial evidence indicates that both Boc-/-
;Cdon-/- and Gas1-/-;Cdon-/- MEFs also show reduced HH response compared to their 
wildtype counterparts (Figure 5.1A).  Gas1-/- MEFs also display reduced HH 
responsiveness compared to wildtype MEFs (Figure 5.1B).  Although Gas1-/-;Cdon-/- 
MEFs have not yet been tested in tumor growth assays, Boc-/-;Cdon-/- and Gas1-/- MEFs 
are able to promote the growth of larger  tumors, similarly to Gas1-/-;Boc-/- MEFs (Figure 
5.1C). Further analysis of the tumor tissue to assess vascularity is ongoing. While this 
data is preliminary, it supports our hypothesis that this effect is a result of HH-dosage 
and not a specific effect of CDON alone.  However, additional experiments with distinct 
Boc-/-;Cdon-/- and Gas1-/-;Cdon-/- MEF lines, as well as single co-receptor knockouts are 
necessary to elucidate the relationship between HH-response and tumor promotion.  
Gas1, Boc, and Cdon have functions aside from their role in the HH signaling 
pathway (3,4). However, evidence supporting the role of the HH-related function of 
these proteins on the development of accelerated, vascularized tumors was provided by 
Rhim et al., who found that KPC;Shhf/f mice develop larger, more vascular tumors than 
172 
 
KPC mice; interestingly, they detected increased Ihh expression in KPC;Shhf/f 
compared to KPC mice (5).  The question then, is whether the generation of a 
KPC;Shhf/f;Ihhf/f mouse, and thus a complete ablation of HH ligands in the neoplastic 
pancreas, would slow tumor progression.  Further, tumor cells derived from tumor-
bearing KPC, KPC;Shhf/f, and KPC;Shhf/f;Ihhff/ mice could be used in co-injection 
experiments with co-receptor knockout MEFs. As the subcutaneous co-injection 
experiments in Chapter Two were performed with tumor cells that expressed Shh, 
additional experiments with tumor cells expressing different amounts of Shh and Ihh 
would strengthen the hypothesis of a dosage-dependent role for paracrine HH signaling 
in pancreatic cancer.   
Additional HH pathway components 
The expression profile of Gas1 and Boc in the adult mouse pancreas mirrors that 
of Gli2 (Figure 5.2A).  Likewise, by crossing reporter alleles of Gli2, Gas1, and Boc into 
KC mice, we see similar expression throughout the stroma during pancreatic 
tumorigenesis (Figure 5.2B).  Hhip expression is also detected by qRT-PCR in the 
neoplastic pancreas of iKras* mice, and its expression decreases upon oncogenic Kras 
inactivation (see Figure 3.11C). However, this expression was determined by qRT-PCR 
of whole pancreatic tissue, and thus the identity of the cells expression Hhip remains 
unclear. Including Gli2-/-, Ptch1+/- and Ptch1+/-;Hhip-/- MEFs in our analysis would allow 
us to test the importance of additional HH pathway components in pancreatic tumor 
growth.   
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Tumor progression 
The work in Chapter two focused on the effect of fibroblast response to HH on 
tumor growth, but did not deeply investigate any possible impact on tumor initiation and 
progression.  Studies on KC;Gas1-/- and KC;Boc+/- mice revealed no overt differences in 
PanIN-formation and stroma accumulation compared to KC mice at 3 weeks following 
caerulein-induced pancreatitis. We also did not detect differences in tissue vascularity at 
this stage between KC, KC;Gas1-/- and KC;Boc+/- pancreata (Figures 5.3A and 5.3B). 
However, generating combination crosses, such as KC;Gas1-/-;Boc+/- would allow us to 
test several aspects of co-receptor function on tumor initiation and progression. First, 
we could test whether expression of the co-receptors completely overlaps in fibroblasts, 
or whether distinct populations exist. Notably, Gas1 and Boc are co-expressed in the 
same fibroblasts in unperturbed pancreas from Gas1+/-;Boc+/- adult mice (Figure 5.4).  
Likewise, we can determine whether Gli2 expression, which is comparable to Gas1 and 
Boc expression in the reactive stroma (Figure 5.2A), is truly co-expressed in the same 
set of cells, and whether distinct subsets exist.  Preliminary analysis of KC;Gli2+/-;Boc+/-
mice three weeks following pancreatitis indicates a population of Gli2+;Boc+ fibroblasts 
in the reactive stroma.   
Second, these crosses also allow us to test the importance of co-receptors on 
earlier stages of tumorigenesis. Mouse crosses to generate these genotypes are 
ongoing. Further, despite the difficulty in detecting the Cdon-LacZ reporter allele as a 
readout of co-receptor expression, crossing it into the KC model to generate additional 
combination knockouts would also allow us to interrogate the importance of all three co-
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receptors on tumor initiation and progression in an autochthonous model of pancreatic 
cancer (see Table 5.1).   
The identity of Gli1-expressing fibroblasts 
In Chapter Three, we investigated the importance on Hedgehog signaling in 
pancreatic recovery, with a particular emphasis on Gli1. In the normal mouse pancreas, 
a small population of Gli1+ cells resides around blood vessels and ducts. During 
tumorigenesis, along with an increased fibroblast population in the reactive stroma, Gli1 
expression is found in an increased subset of these cells (Figure 5.6). Notably, 
expression of Gli1 in the reactive stroma is not as prevalent as that of Gli2, Gas1, and 
Boc (Figure 5.2). Recently, perivascular Gli1-expressing cells were described in several 
organs including the kidney, lung, and heart (6).  In culture, these cells displayed 
multipotency, a hallmark MSC property.  Intriguingly, tissue-resident Gli1+ cells 
contributed significantly to organ fibrosis during induced tissue-damage; the contribution 
of bone-marrow derived cells was excluded through transplantation and parabiosis 
experiments. Specific ablation of Gli1+ cells decreased organ fibrosis, and as 
demonstrated in the heart, partially restored organ function that would normally be 
comprised by irreversible fibrosis (6). The source of organ fibrosis during chronic 
pancreatitis and pancreatic tumorigenesis is unknown. Given that organ fibrosis due to 
chronic pancreatitis is irreversible and increases the risk for pancreatic cancer, 
understanding the source and function of cells contribution to the fibrotic reaction is 
important for development of better clinical treatment.  
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Recently, our lab obtained the Gli1eGFP/+ mouse, which allows FACS-sorting of 
Gli1 expressing fibroblasts (see Fig. 5.7 for scheme); this was not possible using the 
previous LacZ reporter allele. Further, crossing the Gli1eGFP/+ mouse into the KC model 
of pancreatic cancer allowed us to characterize these cells in the context of pancreatic 
tumorigenesis. Preliminary experiments in the lab have found that Gli1+ fibroblasts in 
the pancreas display properties similar to MSCs. First, only Gli1+ fibroblasts FACS-
sorted from the normal pancreas continue to grow in culture; although Gli1- cells are far 
more prevalent in both the tissue and from FACS-sorting, they do not persist in vitro 
(Figure 5.8A). Further, Gli1+ fibroblasts sorted from the both the Gli1eGFP/+ and 
KC;Gli1eGFP/+ mice can differentiate into bone and fat in vitro, thus demonstrating 
multipotency (Figure 5.8B). Further work is ongoing to functionally test the contribution 
of Gli1+ cells to pancreatic desmoplasia and tumor growth.  
Heterogeneity of fibroblasts within the stroma and the response to HH 
The collective body of evidence thus far has revealed that HH signaling in 
pancreatic cancer is more complex than previously thought. While canonical signaling is 
now established to occur in a paracrine manner from the tumor cells to the 
microenvironment, the identity of the HH responsive cells and the nature of their 
response is still not completely understood.  The majority of HH-responsive cells are 
thought to be activated fibroblasts, which are commonly treated as a single 
homogenous group.  In reality, however, activated fibroblasts are a heterogenous set of 
cells (7). Commonly used markers, including αSMA, Vimentin, and PDGFRα are not 
expressed by all CAFs in the microenvironment (7,8). It is possible then, that HH may 
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act upon these subsets in a different manner and elicit differential responses from these 
possible fibroblast subtypes. As the largest group of HH-responsive cells, activated 
fibroblasts have attracted significant research focus. However, while the tumor-to-
fibroblast axis of paracrine hedgehog signaling has been relatively well-characterized, 
the nature of fibroblast response to HH stimulation has not.  Thus, further understanding 
how fibroblast subsets respond to HH is critical to identify downstream pathways of 
possible therapeutic significance, as well as avoid unintended consequences of HH 
inhibition. 
The Gli1eGFP/+ mouse represents a possible system in which to test the differential 
response of fibroblasts to tumor-derived factors, such as HH ligand. After in vitro 
culture, FACS-sorted Gli1+ fibroblasts lose GFP expression, likely due to loss of tissue-
derived signals to induce Gli1 expression. However, treating these fibroblasts with 
tumor-cell conditioned media or HH ligand induces Gli1 expression. Using GFP 
expression, Gli1+ and Gli1- cells can be FACS-sorted and further tested for differences 
between fibroblasts that upregulate Gli1 expression and those that do not.  
In addition to signaling to the tumor cells, fibroblasts also communicate with 
immune cells and can modulate their behavior. Several Gli1 target genes, including IL-
6, Mcp-1, and mIL-8 are expressed by fibroblasts during pancreatic injury, and 
contribute to the recruitment of monocytes/macrophages as well as the polarization of 
macrophages (9). Extending these findings to fibroblast-immune cell communication 
during pancreatic tumorigenesis could identify possible therapeutic targets downstream 
of HH signaling. 
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Finally, the concept that activated fibroblasts promote tumor growth is also in 
question.  Depletion of SMA+ activated fibroblasts led to accelerated pancreatic 
tumorigenesis. Further, although SMA-depleted tumors had reduced levels of vimentin 
and collagen I, these tumors were not sensitized to gemcitabine (10).  While this study 
depleted only SMA+ stromal cells, and thus did not discern between other fibroblast 
subsets nor specific signaling pathways, it did challenge the idea that activated 
fibroblasts in the pancreatic tumor stroma act collectively to promote tumor growth.  
Hedgehog signaling and the immune response to cancer 
In addition to fibroblasts, myeloid cells are another highly prevalent cell 
population in the pancreatic cancer microenvironment (11). In other gastrointestinal 
tissues, HH signaling from the epithelium signals to fibroblasts as well as myeloid cells. 
For instance, in the stomach, H.pylori infection induced HH expression, which acted as 
a myeloid cell chemoattractant (12); mice lacking Gli1 were thus resistant to H. pylori 
induced recruitment to the infected stomach, reducing the overall cytokine response and 
ultimately preventing gastric metaplasia (13). In contrast to the stomach, where 
diminished HH response was protective, reduced response in intestinal myeloid cells 
was harmful. Following induced colitis, Gli1LacZ/+ mice displayed a more dramatic 
cytokine response and consequently more severe intestinal tissue damage (14).  Thus, 
HH-responsive myeloid cells in the gastrointestinal tissues respond to HH in a tissue-
dependant manner. 
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During pancreatic tumorigenesis, a small population of macrophages also 
expressed Gli1 (9). Macrophages act on multiple aspects of tumorigenesis, from 
immunosuppression to chemoresistance (for review, see (15)), and are critical for 
pancreatic tumorigenesis (16). In contrast to fibroblasts, the functional heterogeneity of 
macrophage subpopulations in cancer is recognized and panels of surface markers 
allow for their further study (for review, see (17,18).  However, any functional 
significance of Gli1 positive macrophages compared to their Gli1 negative counterparts 
in pancreatic cancer remains unknown. 
In addition to macrophages, HH signaling can act upon other immune cells in the 
tumor stroma.  For instance, various aspects of T cell behavior including anergy and 
differentiation into functional subsets, may also be affected by Hedgehog signaling (for 
review, see (19)). The effect of HH inhibition on the immune response is an open area 
of investigation. 
Summary 
 Collectively, this dissertation work investigated the role of stromal components on 
pancreatic tumorigenesis. First, I assessed the role of HH co-receptors Boc, Cdon, and 
Gas1 on tumor growth. The role of these co-receptors on HH signaling has been 
studied in development, but remains poorly understood in cancer. Further, the results 
from Chapter Two highlight the importance of considering HH dosage when treating 
pancreatic cancer, as my data indicates that therapeutic benefit is only conferred upon 
almost complete blockade of the HH pathway. Secondly, I investigated the role of HH 
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signaling on pancreatic recovery from injury in Chapter Three. Currently, the most 
common form of pancreatic injury arises from pancreatitis, for which no specific 
treatment exists. While preclinical work indicated that complete HH inhibition in 
pancreatic cancer prolonged survival, I found that HH inhibition during pancreatitis 
precluded proper remodeling of the tissue, leading to residual tissue fibrosis. Finally, in 
Chapter Four, I investigated the presence and function of a specific subset of fibroblast-
like cells – the MSC- on tumor growth. Further, I found that MSCs from the reactive 
stroma could promote the polarization of a tumor-promoting macrophage subtype. 
Taken together, this work sheds light on the complicated role of both the reactive 
stroma and HH signaling on pancreatic tumorigenesis.  
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Figures 
 
Figure 5.1: Dosage-dependent Hh response on tumor growth.  
(A) RT-qPCR analysis of Gli1 and Ptch1 on SHH-stimulated wildtype, Boc-/-;Cdon-/-, 
and Gas1-/-;Cdon-/- MEFs. (B) RT-qPCR analysis of Gli1 and Ptch1 on SHH-
stimulated wildtype, and Gas1-/- MEFs. (C) Growth curve for subcutaneous tumors.  
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Figure 5.2: Gli2 expression is similar to that of Gas1 and Boc in the 
normal and neoplastic pancreas. 
(A) Expression of Gli2LacZ and Gas1LacZ  in the normal pancreas as detected 
by X-gal staining, and expression of BocAP in the normal pancreas as detected 
by Alkaline Phosphatase Staining (far right). Expression of Gli2, Gas1, and 
Boc is detected around blood vessels, ducts, and in scattered cells 
throughoutthe tissue. (B) Expression of Gli2LacZ, Gas1LacZ, and BocAP in the 
neoplastic pancreas indicates similar expansion of positive staining throughout 
the reactive stroma. ).  Scale bars, 50μm 
 
182 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.3: Tissue vascularity is comparable between KC, KC;Gas1Lacz/+ 
and KC;BocAP/+ mice  
(A) Antibody detection of CD31 in pancreata of KC, KC;Gas1Lacz/+, and 
KC;BocAP/+ mice 3w following caerulein-induced pancreatitis. DAPI marks 
nuclei in blue. Scale bar for image and inset 20μm. (B) Quantitation of 
CD31+ stain. Total CD31+ area for each pancreas (n=3) obtained with 
ImagePro Plus Software on five randomized images from each pancreas. 
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Figure 5.4: Boc and Gas1 are expressed by fibroblasts and stellate cells 
in the adult pancreas.  
(A) Single panel images of stains from Gas1LacZ/+;BocAP/AP  for DAPI (blue), β-
gal (green), AP (red), Vimentin (pink). (B) Merged image; white arrows 
indicate co-expression. Scale bar 20μm 
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Figure 5.5: Boc and Gli2 are expressed by fibroblasts in the stroma. 
Analysis of KC;BocAP/+;Gli2LacZ/+ pancreas three weeks following caerulein-
induced pancreatitis. (A) H&E (B) staining for Gli2 expression (C) AP staining 
for Boc expression. (D) Co-immunofluorescnece for Gli2 (green), Boc (red), 
and Vimentin (pink).  Scale bars, black: 50μm; white: 20μm. 
 
185 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.6: Gli1 is expressed in the reactive stroma. 
Analysis of KC (left) and KC;Gli1LacZ/+ pancreas (right) three weeks following 
caerulein-induced pancreatitis. H&E staining (left) and X-gal staining (right) 
Scale bars, 50μm. 
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Figure 5.7: Gli1+ fibroblasts can be sorted from the pancreas.  
Gli1+ fibroblasts can be sorted from the pancreas by negative selection for 
immune cell markers F4/80, CD11b, and CD3.  
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Figure 5.8: Gli1+ cells exhibit MSC-like properties in vitro.  
(A) GFP+ fibroblasts persist in vitro while GFP- fibroblasts do not.  Cells were 
sorted from a KC;Gli1eGFP/+ mouse 1w after caerulein-induced pancreatitis. 
Scale bar, 250μm. (B) GFP+ cells from Gli1eGFP/+ mice (left) and from 
KC;Gli1eGFP/+ mice (right) are multipotent in vitro.  
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Table 5.1: Genotypes to test the effect of HH dosage on 
pancreatic tumor progression 
Genotype Co-receptor Status 
KC All three co-receptors present 
KC;Gas1+/- Missing one copy of Gas1 
KC;Boc+/- Missing one copy of Boc 
KC;Boc+/- Missing both copies of Boc 
KC;Cdon+/- Missing one copy of Cdon 
KC;Gas1+/-;Cdon+/- 
Missing one copy of Gas1 and one 
copy of Cdon 
KC;Boc+/-;Cdon+/- 
Missing one copy of Boc and one copy 
of Cdon 
KC;Boc-/-;Cdon+/- 
Missing both copies of Boc and one 
copy of Cdon 
KC;Gas1+/-;Cdon+/- 
Missing one copy of Gas1 and one 
copy of Cdon 
KC;Gas1+/-;Boc+/- 
Missing one copy of Gas1 and one 
copy of Boc 
KC;Gas1+/-;Boc-/- 
Missing one copy of Gas1 and both 
copies of Boc 
KC;Gas1+/-;Cdon+/-;Boc+/- 
Missing one copy of Gas1, Cdon, and 
Boc 
KC;Gas1+/-;Cdon+/-;Boc-/- 
Missing one copy of Gas1, Cdon, and 
both copies of Boc 
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